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Abstract
The solid-state form can directly affect the quality of a pharmaceutical
product, and solid-state transformations can lead to reduced or unpredictable
therapeutic effects. Formulation and manufacturing processes can impact
solid-state stability. In the pharmaceutical industry there is a need to detect,
quantify and control the solid-state behaviour of powders during processes
and storage. Reliable and convenient analytical methods are crucial. The
overall aim of this thesis was to evaluate strategies for controlling stability and
analysing solid-state forms in pharmaceutical powders. New excipients for
stabilisation of spray-dried protein formulations, as well as Raman
spectroscopy-based methods for solid-state quantification, new in the
pharmaceutical field, were investigated.
Melibiose and isomalt were evaluated as possible new stabilising excipients
for spray-dried protein formulations. The process behaviour of these two
carbohydrates, and the physical stability of amorphous isomalt and melibiose
powders were evaluated in comparison to sucrose and trehalose. Both could
be spray dried into amorphous powders, but melibiose was more applicable
for spray drying processes and showed better physical stability than isomalt.
In the subsequent study, the protein-stabilising efficacy and process
behaviour of melibiose in spray-dried protein formulations was investigated
in comparison to the current standard protein-stabilising excipient, trehalose.
Protein formulations with melibiose could be spray dried into amorphous
powders that were physically stable, contained lower moisture contents and
protected protein activity at least as well as formulations with trehalose.
Low-frequency Raman spectroscopy for quantitative analysis of solid-state
form mixtures was investigated, in order to evaluate its potential advantage
over the established mid-frequency Raman spectroscopy analysis. Standard
spectral processing and multivariate data analysis methods were used. Low-
frequency Raman spectroscopy was found better than conventional mid-
frequency Raman spectroscopy analysis, because of higher signal intensity and
solid-state sensitivity.
In the final study, time-gated Raman spectroscopy was tested for
quantitative solid-state analysis of fluorescent pharmaceutical powder
mixtures. Fluorescence interference occasionally limits the feasibility of
conventional Raman spectroscopy analysis. Both standard multivariate
analysis methods as well as kernel-based methods were used for data analysis.
It was found that time-gated Raman spectroscopy, particularly when
combined with kernel-based data analysis methods, provided benefits for the
quantitative analysis of materials suffering from fluorescence.
In summary, melibiose was identified as a promising excipient to stabilise
spray-dried protein formulations. Low-frequency and time-gated Raman
spectroscopy were found advantageous for solid-state analysis, also with
fluorescent materials, and they may be useful techniques for various solid-
state monitoring applications.
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11 Introduction
Solid-state properties are critically important in pharmaceutical product
development and manufacturing, because they can directly affect the quality
of a drug product [1, 2]. Common to the diverse types of pharmaceutical solids
is that solid-state transformations can lead to reduced or unpredictable
therapeutic effects. Such changes can affect the active pharmaceutical
ingredient directly (e.g. different physicochemical properties of different
forms) or indirectly (e.g. by influencing the stability of the product). There is a
need to understand, control and monitor solid-state behaviour during
pharmaceutical processes and storage. Formulation and manufacturing
processes affect the solid-state structure, and they must be designed so that
the product has the intended properties that also remain stable during storage.
Reliable analytical methods for solid-state characterisation are crucial.
Therapeutic proteins have become a major drug class in the pharmaceutical
industry. The biological activity of proteins is determined by their molecular
conformation, which is sensitive to various instabilities. Degradation of the
native structure and formation of protein aggregates can result in loss of
activity or harmful immunologic responses. Some degradation pathways can
be inhibited by drying, but the drying process itself, as well as storage in the
dried state, can also be harmful to proteins. Stabilising excipients are generally
needed to preserve the protein structure and activity. Low-molecular-weight
compounds that are efficient in hydrogen bonding with the protein are often
good stabilisers, provided that they form an amorphous singe-phase matrix
structure [3]. Disaccharides, such as trehalose and sucrose, are often used for
this purpose. With amorphous systems, stability becomes a concern, because
they may spontaneously convert to a thermodynamically more stable form (i.e.
crystallise). The likelihood of crystallisation can be affected by choice of
formulation excipients and processing conditions.
Spray-drying  is  an  increasingly  used  drying  technology  in  the
biopharmaceutical industry, with advantages in speed and cost-efficiency of
the process and control over dried particle properties [4]. Spray-drying is
potentially suitable for proteins but the process parameters must be carefully
chosen to ensure preservation of protein activity. Furthermore, process
parameters can affect the solid-state properties of the resulting powder and
the physical stability of the formulation. For stable dry protein formulations,
both the drying process and formulation must be optimized.
Trehalose and sucrose are commonly used stabilising excipients for solid
protein formulations, but problems with crystallisation may arise during
storage [5-7]. Alternative excipients should be evaluated to potentially
broaden the current selection of formulation excipients. Melibiose and isomalt
have shown potential in freeze-dried protein preparations but have not been
tested with spray drying. Information on their spray-drying process
behaviour, protein-stabilising efficacy and physical stability is needed.
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As with large biomolecules, the structure of small molecule drugs (below
500 Daltons) determines the biological activity, but small molecules are
generally more chemically stable. What can become more critical than
degradation of the molecular structure, is the packing arrangement of the
molecules in solids [8, 9]. The degree of order (crystalline or amorphous) as
well as the characteristic lattice structure of different crystal forms (e.g.
alternative polymorphs and solvates) result in different intermolecular
interactions, which determine the physicochemical properties of the solid
affecting e.g. the (apparent) solubility, stability and processability of the drug.
Designing products with the active ingredient in an unstable solid-state form
has become increasingly popular because a growing portion of new molecules
in development have very limited solubility [10, 11]. These forms may have
improved solubility, but they are inherently unstable, thermodynamically
driven to convert into a more stable form. Production of different solid-state
forms and their storage stability is controlled by manufacturing processes and
formulation. Solid-state transformations, which could lead to unacceptable
changes in product properties, can happen and need to be detected.
Given the importance of solid-state forms in different settings, there are
numerous analytical tools for evaluating solid-state behaviour. Commonly
used methods include thermal analysis, diffractometric and spectroscopic
techniques [12]. Despite the availability of current techniques, there is a
demand for advances in the field. Driving factors include the desire for
reduced time and sample consumption of analyses, overcoming specific
limitations of the techniques, as well as better in-line measurements for real-
time process monitoring. Raman spectroscopy has become an established
process monitoring tool in pharmaceutical industry because of its potential for
fast, non-destructive measurements that can be performed from inside
manufacturing vessels or product containers [13]. Limitations of conventional
Raman spectroscopy include low sensitivity or signal deterioration caused by
photoluminescence, such as fluorescence, of some materials.
Developments in instrumentation which allow measurement of a wider
spectral range (access to the low-frequency or terahertz region [14, 15]) and
separation of the Raman and photoluminescence signals (by time-resolved
detection [16]), may result in even more wide-spread applicability of Raman
spectroscopy. Unlike conventional mid-frequency Raman spectroscopy, low-
frequency Raman spectroscopy probes low-energy lattice vibrations that are
directly defined by the crystal structure, and therefore it can be particularly
useful for solid-state analysis. Time-gated Raman spectroscopy may provide
better analyses of fluorescent materials. The potential of these two more
recently available Raman techniques should be further evaluated in the
pharmaceutical setting. Multivariate data analysis methods have improved the
potential for qualitative and quantitative interpretation of spectra [17].
Developments in chemometric methods may allow further advantages [18],
and they should be actively investigated and implemented when appropriate
also in the pharmaceutical research field.
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2.1 Pharmaceutical solids
Orally administered solid dosage forms, including tablets and capsules, are the
most commonly used drug delivery systems [19]. They are convenient,
acceptable and comparatively safe for the patient, can be cost-efficiently
manufactured, are versatile with respect to design, and are relatively
chemically and physically stable compared to e.g. liquid formulations [2]. In
cases where oral administration does not allow adequate bioavailability,
because of insufficient gastrointestinal wall permeation or degradation of the
drug by the first-pass effect, other methods of administration are required. An
example is protein drugs, for which the parenteral route by injection is the
primary choice. The main component in parenteral formulations is usually
water, which increases many degradation route rates. Thus, the preparation of
solid dosage forms via water removal is also often essential with these products
to obtain adequate stability during shipping and storage [20].
Solid dosage forms are thus extremely commonly encountered in the
pharmaceutical industry and the manufacturing of practically all solid dosage
forms  involves  working  with  powders.  Powders  may  be  used  as  the  final
product or they can be intermediates before e.g. compression to tablets.
Pharmaceutical powders are composed of solid particles and air, and they
often contain a mixture of materials: active pharmaceutical ingredient(s)
(API) and excipient(s). Several properties govern the process behaviour of
powders as well as the final product performance. Internal solid-state
structure is one such important property.
2.1.1 Different solid-state forms
Solid  materials  can  exist  in  various  solid-state  forms  (FIG  1); these are
determined by the packing arrangement of the molecules [1, 2, 21]. A first level
classification can be made by separating crystalline and amorphous forms. In
crystalline materials, the molecules are arranged in a defined order with
elements of symmetry and the arrangement forms a repeating pattern in three
dimensions (the crystal lattice). Amorphous solids lack such long-range order,
even if they may exhibit short range order including favoured intermolecular
interactions. Small molecules often exist in crystalline form, with the
amorphous form being thermodynamically unstable [22]. In contrast,
materials composed of large molecules, such as polymers or proteins, are more
often amorphous because the size and flexibility of these molecules makes
alignment into perfect order difficult. Polymeric materials often, however,
show ordered regions, surrounded by disorder, and such a structure is
Review of the literature
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described as semicrystalline. In reality all pharmaceutical solids usually have
both crystalline and amorphous content.
Figure 1 Different solid-state forms of pharmaceutical materials. Amorphous hydrates/solvates
have variable quantities of water/solvent, they are not stoichiometric hydrates/solvates like the
ordered crystalline ones. Modified from Healy et al., 2017 [1, 8, 21, 23].
Most organic crystalline compounds exhibit polymorphism [24]. Different
polymorphic forms have the same chemical composition, but the orientational
and positional order of the molecules that define the crystal structure varies.
There is one thermodynamically stable polymorphic form at a given
temperature and pressure, while all other crystal forms are metastable, and
they will eventually convert to the stable form. At ambient pressure when the
same solid state form is the stable form at all temperatures below its melting
point, this is called monotropic polymorphism. In the alternative case of
enantiotropic polymorphism, the stable form depends on temperature [2].
Both crystalline and amorphous solids can be composed of a single or
multiple chemical components. Commonly encountered crystalline
multicomponent solids include solvates and co-crystals. The term ‘hydrate’ is
used when the secondary molecule is water [1]. Amorphous multi-component
systems can be classified depending on e.g. the number of phases in the system
(single-phase glass solutions and double-phase glass suspensions [21]), or the
molecular weight of the co-former (low molecular weight for co-amorphous
mixtures [23]).
An important difference between the solid-state forms (and a way to
classify them) is the variation in the intermolecular interactions within the
structures. The nature of the intermolecular bonds can be ionic or covalent
5(e.g. hydrogen bonds, Ⱥ-Ⱥ-interactions) depending on the molecules involved,
distinguishing salts from other multicomponent forms. The strength of the
intermolecular forces varies between different polymorphs and the
amorphous form of the same compound, because of differences in the
functional groups involved and/or the distance separating the molecules.
These interactions determine the thermodynamic parameters and many
physicochemical properties of the compounds.
2.1.2 Significance in the pharmaceutical setting
Different solid state forms are a major concern in the pharmaceutical industry
since they can significantly affect the drug product quality in terms of
bioavailability, stability and processability, as well as having regulatory, legal
and commercial (including intellectual property) implications [8, 9].
The difference in the intermolecular forces can result in significant
variation of the physicochemical properties between different solid-state
forms of a material. Collectively, the interactions are stronger in the
thermodynamically stable crystalline form compared to metastable
polymorphs or the amorphous form, which results in a higher melting point
(for monotropic systems), but lower solubility and dissolution rate. Hydrates
often show lower solubility compared to anhydrate forms [2]. The molecular
order and packing can also affect the crystal habit and particle morphology,
influencing mechanical properties such as powder flowability or
compressibility [8, 25]. Amorphous materials are often more hygroscopic
compared to crystalline forms. The powder characteristics and the
performance of drug products can depend on the solid-state forms of both the
APIs and excipients.
Considering  the  API,  solid  form  selection  has  a  crucial  role  in  the
development of a commercial pharmaceutical product [8, 9, 26]. Usually the
thermodynamically most stable form is selected, in order to maximise the
product stability. However, new drug candidates often present poor water
solubility, and the dissolution rate may not be adequate to achieve good
bioavailability. One strategy to improve the bioavailability with poorly soluble
drugs is to select a metastable solid state form, or most commonly the unstable
amorphous form [11]. The disadvantage with these forms is their inherently
lower physical and chemical stability [8, 9]. Particularly hygroscopic
amorphous materials demonstrate poor stability, since the absorbed moisture
acts as a plasticizer, increasing chemical reactivity and the propensity to
crystallise. Improved stability for the drug in the amorphous form may be
provided by solid dispersion formulations, where the drug is molecularly
dispersed with polymers [10, 11] or with low molecular weight compounds in
co-amorphous mixtures [23]. In these approaches physical stability is still
often a concern, however, since crystallisation of the drug during storage
would negatively impact the therapeutic efficacy of the product.
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With solid protein formulations, it is the solid-state form of excipients that
may be crucial for product stability and performance. Stabilisation of proteins
in the dried state usually requires interactions with stabilising excipients, only
possible when the excipient and protein molecules both are in the same
amorphous phase [27, 28]. Crystallisation of the stabilising excipient may lead
to protein aggregation and loss of therapeutic activity [6, 29].
Where the solid state forms of the drug or excipients are critical to product
stability or efficacy, they must be maintained appropriately through the drug
product processing steps. However, it is not uncommon for solid-state
transformations to occur during pharmaceutical processing or storage, and
they are relevant concerns for the industry [12, 26, 30, 31]. Pharmaceutical
manufacturing may involve several unit operations (e.g. milling, wet
granulation, drying, tablet compression), which involve mechanical and
thermal stresses, as well as exposure to solvents, which may induce various
types of solid state changes (FIG 2).
Figure 2 Process-induced solid-state transformations. Modified from Govindarajan and
Suryanarayanan 2006 [32].
It is more common to obtain mixtures of solid forms rather than full
conversions, with the occurrence of hydrate-anhydrate mixtures being one of
the biggest challenges during routine processes [8, 26, 33, 34]. Furthermore,
an issue concerning excipients in particular, is that the solid state form may
vary between different suppliers [26]. The assessment of solid-state forms and
their stability in solid dosage forms during manufacturing and storage,
including early detection and quantification of transformations, is essential to
ensure the quality of the final product. Process measurements that provide
insight into events occurring during unit operations, as highlighted in the
process analytical technology (PAT) concept [35], are valuable for
understanding, controlling and optimising the processes, which are critical in
ensuring product quality.
72.1.3 Solid-state characterisation techniques
Several solid-state analysis techniques are used to characterise
pharmaceutical materials and monitor their behaviour in different processes
and formulations. A combination of techniques is generally required, and the
choices depend on the level of understanding needed. The most commonly
used methods for solid state characterisation have been X-ray powder
diffraction (XRPD), differential scanning calorimetry (DSC), mid-infrared
spectroscopy (Fourier-transform infrared, FT-IR) and microscopy, which
cover many physicochemical properties on both the molecular and particle
levels [12]. Other routine techniques in pharmaceutical solid state analysis are
Raman spectroscopy, near-infrared spectroscopy (NIR), solid-state nuclear
magnetic resonance (ss-NMR) and thermogravimetric analysis (TGA) or
dynamic vapour sorption (DVS). Spectroscopic methods are particularly
useful as process monitoring and control (PAT) tools [36]. Analytical
techniques important in pharmaceutical powder technology are listed in
Table 1, categorised based on the properties investigated: molecular level
(properties of individual molecules), particle level (individual particles) and
bulk level (assembly of particles).
Distinguishing between amorphous and crystalline materials is one
important goal. The difference (lack) in long range order of molecular packing
can be observed with various methods, though sensitivity differs. Some
general rules are that amorphous materials do not give peaks in XRPD
diffractograms because of the lack of in-phase reflections from crystal planes.
Crystalline materials have characteristic melting points (depending on the
amount of energy required to break the attractive forces in the crystal lattice),
but amorphous materials do not melt because there is no crystal lattice to
break. Instead, amorphous materials show a glass transition (Tg) at the
temperature where the material transforms from a glassy state (the solid-like
form) to a supercooled liquid state (a viscous liquid-like form) on heating [22].
Amorphous materials can also be identified by other methods, including
vibrational spectroscopy techniques, where the differences in intermolecular
bonding between different solid state forms result e.g. in vibrational band
broadening in the mid-frequency spectral region or in the absence of distinct
features in the terahertz spectral region [37].
Review of the literature
8
Table 1. Characterisation techniques commonly used for solid-state analysis of
pharmaceuticals. Modified from Chieng et al. 2011 and Heinz et al. 2009 [12, 30].
Technique Information provided Advantage Disadvantage
Molecular level
Spectroscopic techniques
Mid-IR
(FTIR
transmission,
DRIFTS,
ATR)
Intramolecular vibrations, H-
bonding (dipole moment
changes)
Polymorphic forms: unique
bands, peak shifting
Amorphous form: band
broadening
No sample preparation
(ATR)
Fast measurements
Chemical identification
Spatial information with
imaging setups
Complementary structural
information to Raman
spectroscopy
Solid-state transitions
possible with sample
preparation
(transmission or
DRIFTS modes)
Interference from
humidity and
excipients
Raman Intramolecular vibrations
(polarizability changes)
Polymorphic forms: unique
bands, peak shifting
Amorphous form: band
broadening
No sample preparation
Fast measurements
Non-destructive
Ability to penetrate through
containers
Insensitive to water
Relatively insensitive to
particle size
Fibre optic probes available -
PAT
Chemical identification, and
at low frequencies also
lattice vibrations
Spatial information with
imaging setups
Complementary structural
information to IR
spectroscopy
Local heating of
sample
Sample fluorescence
Photodegradation
Near infrared
(NIR)
Overtones and combinations
of molecular vibrations (dipole
moment changes)
Polymorphs and solvates:
band splitting, changes in
molecular symmetry
Solvates: loss of solvent
bands during dehydration
identification of different states
of water
Amorphous forms: band
broadening, lack of low-
frequency bands
No sample preparation
Fast measurements
Non-destructive
Ability to penetrate through
containers
Fibre optic probes available
– PAT
Also particle size and, water
content information
Spatial chemical information
with imaging setups
Low sensitivity and
selectivity (low
intensity)
Subtle differences
between solid state
forms
Affected by water and
particle size
ss-NMR Magnetic resonance
Nuclei and chemical
environment within a molecule
Molecular dynamics
Interactions: drug-drug or
drug-excipient
Non-destructive
Qualitative and quantitative
without calibration
Long measurements
Expensive
Particulate level
Spectroscopy
Terahertz
pulsed
spectroscopy
(TPS)
(transmission
, ATR,
specular
reflectance)
Intramolecular and
intermolecular, lattice
vibrations (phonon modes)
Polymorphic forms and
solvates: unique peaks
Amorphous form: no spectral
features
Information about crystal
structure
Fast measurements
No sample preparation
(ATR)
Affected by water,
particle size
Spectra may be
difficult to interpret
Relatively expensive
May require sample
preparation
9X-ray diffraction
XRPD Structural information
Polymorphic forms: unique
diffraction peaks
Amorphous form: no peaks,
broad halo
Standard method for crystal
form identification
Quantification of the degree
of crystallinity
Non-destructive
Affected by particle
size and orientation
(preferred orientation)
No chemical
information
Probes not common
Single crystal
XRD
Structural information Traditionally used to solve
crystal structures
Non-destructive
Requires a single
crystal of >0.1 mm
size
Thermal and gravimetric analysis
DSC Thermal events: Tg,
crystallisation, melting, heat
capacity
Interactions: drug-drug, drug-
excipient
(heat flow vs temperature)
Sensitive
Qualitative and quantitative
about relative stability
Destructive
May be difficult to
interpret
Impurities can affect
Modulated-
temperature
DSC
As DSC, with separation into
reversible and non-reversible
thermal events
Allows better interpretation
of small (Tg) and overlapping
thermal events
More experimental
variables
Longer measurements
Interpretation may not
be straightforward
TGA/DVS Transitions involving a change
in mass
(mass vs temperature or
relative humidity)
Amount of solvates and
hydrates in a sample
Sensitive
Destructive
Interference with
water-containing
excipients
Isothermal
micro-
calorimetry
(IMC)
Heat change in a reaction: e.g.
enthalpy relaxation of
amorphous materials, heat of
crystallization
(heat flow vs time)
High sensitivity
Qualitative and quantitative
Stability studies
Low specificity
Large sample amounts
Solution
calorimetry
(SC)
Heat change in a reaction: e.g.
heat of solution, heat of
wetting, heat capacity
(heat flow during dissolution)
Qualitative and quantitative Low specificity
Large sample amounts
Destructive
Long measurements
Microscopy
Polarized
light
microscopy
(PLM)
Crystallinity (birefringence)
Morphology, colour, crystal
habit
Little sample preparation
Easy
Not quantitative
With hot /
cryo / freeze
drying stage
Complementary information on
phase transition/physical
changes in frozen state
Temperature variability Careful sample
preparation required
Scanning
electron
microscopy
(SEM)
Topographical properties Higher spatial resolution
than light microscopy
Sample preparation
and condition setup
(vacuum) required
Bulk level/other
Karl Fischer
titration
Water content High sensitivity Sample needs to
dissolve in the medium
Large sample sizes
Brunauer,
Emmett and
Teller (BET)
method
Surface area Simple analysis
Non-destructive
Degassing step
required
Large sample sizes
Density (gas
pycnometer)
True density of the sample
(mass divided by measured
volume)
Simple analysis
Non-destructive
Degassing step
required
Large sample sizes
DRIFTS: diffuse reflectance Fourier transform infrared spectroscopy; ATR: attenuated total
reflection
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2.2 Protein pharmaceuticals
The pharmaceutical industry has shifted from a small molecule-centric focus
to a portfolio with equal shares of small molecules and biologics, and most
major pharmaceutical companies are now involved with development of
biological drugs, particularly protein therapeutics [38]. Compared with small
molecules, proteins are large, complex and unstable. The inherent instability
poses challenges for manufacturing operations, handling and storage, since
protein degradation can result not only into loss of therapeutic activity, but
also increased potential of stimulating adverse immune responses, a unique
safety concern for protein therapeutics [39, 40]. The rate of degradation can
be controlled by choice of proper formulation excipients and conditions [41].
The formulation must maintain the safety and efficacy of the product
throughout the commercial distribution system, with adequate shelf life [42].
2.2.1 Protein structure and stability
Proteins are very versatile biomolecules, composed of different amino acids
joined covalently through peptide bonds to form long polymers with a
molecular weight above 10 000 [43]. Smaller amino acid polymers are referred
to as polypeptides. Proteins present several levels of structure: 1) the amino
acid sequence (primary structure), 2) the regular arrangement of amino acid
residues in a segment of the polypeptide chain (secondary structure), 3) the
complete three-dimensional folding structure, and 4) the arrangement of
subunits in case of multisubunit proteins (quaternary structure). The unique
three-dimensional structure reflects the specific function of each protein.
The folding arrangement or conformation is stabilised by weak
interactions, resulting in the inherent instability of proteins. The polymeric
structure is flexible and different conformations are possible without breaking
covalent bonds. With soluble, globular proteins (representing therapeutic
proteins) the folded structure is typically characterised by hydrophobic amino
acid residues buried in the core of the structure and their exposure to the
solvent minimised, while the surface is dominated by hydrophilic groups. The
major contributors to the thermodynamic stability of this so-called native
structure are the hydrophobic interactions, while hydrogen bonds and ionic
interactions may provide additional stability [43]. This structure has evolved
to function in particular cellular or extracellular environments, and conditions
different from those often result in structural changes. A change in structure
sufficient to cause loss of function is called denaturation. Denaturation can be
reversible, however the exposure and interaction of the hydrophobic patches
often results in irreversible aggregation or precipitation. Aggregation is a
major concern when handling proteins and in the development of stable
protein therapeutics [42, 44].
All proteins are subject to various instabilities that can lead to aggregation
or other structural damage (FIG  3). The degradation mechanisms can be
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generally divided into two categories, physical and chemical instabilities,
however they are usually interrelated [38, 45]. Physical instabilities refer to
changes in structure not requiring covalent modifications, while chemical
degradation involves bond formation or cleavage. The tendency for
degradation depends on the individual sequence of a protein [46]. The
susceptibility of different amino acids to chemical reactions and contribution
to aggregation varies, and their position in the protein structure determines
their availability for degradation processes. Degradation rates are also largely
affected by external factors, such as temperature, pH, exposure to surfaces or
mechanical stresses including agitation and high-shear environments (e.g.
pumping, filtration, mixing, fill-finish processes), freezing and drying [42].
Furthermore, the protein concentration affects aggregation tendency.
Figure 3 Common physical and chemical degradation mechanisms with pharmaceutical
proteins. Modified from Ohtake and Wang 2014 [42].
2.2.2 Formulation strategies
The major aim for protein formulation development is to minimise the rate of
all protein degradation processes and thereby optimise the stability of the
native protein conformation during processing and storage, to meet the overall
requirements for the target product profile [42, 46, 47]. Various excipients
may be included in the formulation to protect the protein (Table 2). Liquids
and freeze-dried solids present the two major product forms for commercial
protein therapeutics. This is because most protein drugs are administered
parenterally, and aqueous solutions are the standard formulation type in this
context [48]. Approximately half of the commercial products are liquids and
the other half are solid dosage forms prepared by lyophilisation [49].
Alternative manufacturing technologies, including spray drying, have been
applied for the development of specific drug delivery options e.g., pulmonary
or nasal delivery and parenteral depots [4, 46, 48].
Review of the literature
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Table 2. Examples of formulation components in commercial pharmaceutical protein products,
including cytokine, antibody (mAbs, fragment fusion proteins and conjugates), hormone and
enzyme products [3, 46, 50].
Category Examples Purpose
Buffers acetate
citrate
succinate
phosphate
histidine
glutamate
Tris
carbonate
lactate
pH control
Salts sodium chloride
potassium chloride
Ionic strength and tonicity modifiers
Surfactants polysorbate 80
polysorbate 20
poloxamer 188
SDS
Minimize aggregate formation at
hydrophobic air-water interfacial
surfaces. Poloxamer also increases
viscosity, providing protein protection
during agitation
Antioxidants EDTA
citric acid
methionine
tryptophan
Chelating agents (EDTA, citric acid)
Oxygen scavengers (methionine,
tryptophan)
Sugars, polyols sucrose
trehalose
mannitol
sorbitol
maltose
lactose
Protein stabilisers/lyoprotectants
Lyophilisation bulking agents
Tonicity modifiers
Amino acids glycine
histidine
arginine
lysine
methionine
Protein stabilisers
Buffer components
Antioxidants
Tonicity modifiers
Bulking agent (glycine)
Polymers and proteins polyethylene glycol
human serum albumin
Protein stabiliser
Lyophilisation bulking agents
Increased viscosity, steric hindrance
of protein-protein interactions,
suppression of pH changes during
freezing
Metal ions zinc Protein stabiliser (specific ligand)
Preservatives benzyl alcohol
m-cresol
phenol
Prevent microbial growth in multi-
dose products
EDTA: ethylenediaminetetraacetic acid, SDS: sodium dodecyl sulfate
Liquid formulations are typically preferred for products administered by
injection due to simpler manufacturing and use, but they are generally less
stable than solid dosage forms [42, 46]. Dried formulations are developed
when the shelf life of the liquid dosage form is inadequate. Another reason for
preparing dried products is when highly concentrated protein formulations
are needed [48]. A general formulation strategy may proceed as outlined by
Winter and Myschik 2012 [48]:
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1) Buffer selection with adjustment to optimal pH and ionic strength, along
with oxygen removal by nitrogen gassing may be sufficient to obtain a
formulation with adequate stability. Multi-dose products require inclusion
of a preservative.
2) If buffers and salts do not give sufficient stability (commonly presented as
protein aggregation, oxidation or fragmentation), more active formulation
measures are needed. Typically the next step is the addition of surfactants
and antioxidants or chelating agents (methionine or EDTA).
3) If instability persists, additional stabilising excipients are required. Sugars,
polyols, and amino acids (particularly glycine) are often used to stabilise
proteins in aqueous solution. It is believed that these compounds (co-
solutes) provide active stabilisation of the native conformation by the so-
called preferential exclusion mechanism [51]. According to the theory, co-
solutes inhibit protein unfolding by increasing the free energy difference
between the native and unfolded states, thereby making the free energy of
denaturation greater and thermodynamically unfavourable. In order to do
this, there must be a high enough concentration of co-solutes and they
must be preferentially excluded from the protein surface (i.e. not interact
strongly), leaving the surface to be hydrated by water. As a result, the
protein is surrounded by more structured water, leading to a decrease in
system entropy. Unfolded states of the protein have larger surface areas
exposed to the solvent compared to the native state. Denaturation would
therefore  lead  to  an  even  greater  decrease  in  entropy,  and  thus  the
equilibrium between conformations shifts to more substantially favour the
native state. Some stabilisers like arginine may also prevent aggregation
and increase protein solubility through direct interactions [52, 53].
4) If long-term stability cannot be obtained in liquid formulation even with
stabilisers, a dried (lyophilised) formulation may be developed. Similar
formulations as with liquid products are used, however the freezing and
drying as well as storage in the dried state may result in additional
demands concerning the solid state properties of the formulation
components. Crystallisation of buffer components causing pH shifts
(particularly common with phosphate buffers) or other excipients can
reduce product stability. With lyophilised formulations, a bulking agent is
always required to confer an acceptable cake of high quality and production
of a uniform powder that can easily be reconstituted [42, 49]. Mannitol and
glycine are commonly used for this purpose. However, they might not
provide sufficient stability to the protein in the dried state, since they
crystallise during lyophilisation. Additional stabilising excipients (e.g.
disaccharides or polymers) which remain amorphous are often required
[49]. The relative amount of formulation components needs to be
optimised, since they affect each other’s solid state behaviour and stability
(as well as tonicity) of the protein product.
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2.2.3 Carbohydrates as stabilising excipients in dried formulations
Drying improves the shelf life stability of protein products because the removal
of water decreases chemical degradation rates. Certain physical stresses, e.g.
agitation and air-water interfacial stresses during shipping and storage, are
also alleviated compared to liquid products, and dried products have better
stability against temperature excursions [45]. However, drying and storage in
the dried state causes other major stresses to proteins [41, 54, 55]. The main
contributor affording thermodynamic stability to the native conformation
(limiting solvent exposure of hydrophobic groups) is lost when the protein
molecule is no longer in its natural aqueous environment. This increases the
probability of unfolding. Since drying also results in a protein concentration
increase, interactions between unfolded proteins become more probable than
in dilute aqueous solutions, making aggregation a likely outcome. To stabilise
proteins against these drying stresses, stabilisers called lyoprotectants are
often needed. Carbohydrates generally perform well in this role [51, 54-56].
For optimal stabilisation efficacy, it is important for the stabilisers to be in
the amorphous form and in the same phase with the proteins [27, 28, 57]. This
allows kinetic immobilisation of the proteins in the glassy matrix, which
inhibits molecular mobility, including unfolding, and protein-protein
interactions that could lead to aggregation. Both polymeric and smaller
carbohydrates can form such matrices.
However, disaccharides are the first choice for protection of solid protein
formulations during storage [42, 49, 55]. This is because the glassy state is not
sufficient for optimal stabilisation, but additionally direct coupling between
the excipient and protein is important [57]. It is believed that the hydroxyl
groups of carbohydrates hydrogen bond with the protein, and thus replace the
interactions lost during removal of the hydration layer [54]. Protein
stabilisation efficacy is dependent on excipient molecular weight, and larger
molecules (with the same functional groups, e.g. dextran) commonly provide
less efficient stabilisation [3, 58-63]. Smaller carbohydrates can get closer to
the protein surfaces than polymers, and can thus better provide direct
interactions. Additionally, there is less free space for protein mobility in the
solid with disaccharides than with polymers.
The two requirements for stabilisation are interrelated. The amorphous
structure allows more intimate contacts between the proteins and stabilisers
and a higher possibility for the direct interactions, since the molecule positions
are less constrained. There are also more hydroxyl groups available for
interactions with the protein since they are not occupied in crystalline
intermolecular interactions.
Among disaccharides, trehalose and sucrose are the common choices in
commercial protein products [42, 44, 46, 49]. One reason for this is that they
are non-reducing sugars, which is preferable for protein formulations, to
reduce the risk of chemical degradation of proteins via the Maillard reaction
route. However, the reducing sugars lactose and maltose have also
occasionally been used in products (maltose with mAbs [46] and lactose with
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an enzyme [3]) and they can provide equally good stabilising efficacy as
trehalose [46].
Another reason for choosing trehalose and sucrose is that they both have a
relatively high Tg for  a  sugar  [64]  and  they  do  not  crystallise  easily  during
lyophilisation [46]. However, trehalose and sucrose crystallisation and
resultant protein aggregation may happen during storage or further
processing [5, 65]. Particularly with spray-dried formulations, ratios of
sucrose or trehalose to protein that are too high can decrease protein stability
during storage due to crystallisation [6, 29, 66].
2.2.4 Isomalt and melibiose
Isomalt is a polyol derived from sucrose, and produced by hydrogenating the
disaccharide isomaltulose [67]. It is used in the food and pharmaceutical
industries, e.g. in sugar-free products and as a tablet excipient [67-70]. Isomalt
is a mixture of two diastereomers: 1-O-Į-D-glucopyranosyl-D-mannitol
(GPM) and 6-O-Į-D-glucopyranosyl-D-sorbitol (GPS). The physicochemical
properties are similar to those of sucrose and depend on the isomalt
composition (ratio between GPM and GPS). Isomalt is not subject to the
Maillard reaction, making it attractive for protein formulations. Studies
investigating isomalt in dried protein formulations are limited, but it has
shown some potential for protein stabilisation in freeze-dried formulations
during storage [71].
Melibiose is a disaccharide, naturally present in e.g. honey and many
plants, but industrially produced by enzymatic hydrolysis of raffinose, a
trisaccharide found e.g. in agricultural by-products such as cottonseed and
bean pulp [72, 73]. Melibiose is a reducing sugar and it is not commonly used
with dried protein formulations. However, it can stabilise proteins in
lyophilised protein formulations, and no evidence of Maillard reaction-based
protein degradation was observed during a three-month study with
monoclonal antibodies [74, 75]. The structures isomalt, melibiose, sucrose and
trehalose are shown in FIG 4 and some properties listed in Table 3.
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Figure 4 The molecular structures of melibiose, isomalt, trehalose and sucrose. Isomalt is a
mixture of two diastereomers: gluco-mannitol (GPM) and gluco-sorbitol (GPS).
Table 3. Properties of isomalt, melibiose, sucrose and trehalose. References: PubChem,
CCDC, Handbook of Pharmaceutical excipients, and isomalt: [67, 76-78], melibiose: [72, 79-81],
sucrose: [81, 82], trehalose: [64, 65, 83]
Isomalt Melibiose Sucrose Trehalose
Description Non-reducing
mixture of
disaccharide
alcohols GPM
and GPS
Reducing
disaccharide of
galactose and
glucose with Į-1,6-
linkage
Non-reducing
disaccharide of
glucose and
fructose with a Į-1-
2 -linkage
Non-reducing
disaccharide of
two glucose units with Į,
Į-1,1-linkage
Chemical
formula and
molecular
weight
(anhydrous)
C12H24O11
344.3
C12H22O11
342.3
C12H22O11
342.3
C12H22O11
342.3
Solubility soluble in water soluble in water soluble in water soluble in water
Tg (°C)
(anhydrous)
59 (isomalt 1:1)
55 (GPS)
66 (GPM)
100 60 [Ref. 82]
74 [Ref. 81]
120
Crystalline
forms and
their melting
points (°C)
Isomalt (142)
GPM dihydrate
(166)
GPS anhydrate
(168)
Į-melibiose
monohydrate (179-
186),  stable form
ȕ-melibiose
dihydrate (85-86)
anhydrate (160-
186)
dihydrate (97-100;
dehydration), stable
hydrate form
ȕ–anhydrate (205-215),
stable anhydrous form
Į–anhydrate (126)
Ȗ forma (120; transition
to ȕ anhydrate)
a Possibly a mixture of the dihydrate and ȕ-anhydrate forms.
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Neither isomalt nor melibiose are currently used in commercial
pharmaceutical protein products. Their safety and toxicological aspects have
not been fully characterised in terms of possible use as stabilising excipients
for protein products, typically administered via the parenteral route.
Isomalt has regulatory approval as a food additive in all major regions of
the world [67, 84]. It is also used as an excipient in pharmaceutical products
approved  in  the  US  and  in  EU  countries  [85,  86],  and  it  is  included  in  the
European and US pharmacopoeias [87, 88]. Isomalt has been found safe when
administered orally, also considering chronic toxicity [89-92]. The safety of
parenteral administration of isomalt is less studied, but regarding acute
toxicity, the LD50 dose in rats has been reported to be over 2500 mg/kg when
administered intraveneously or intraperitoneally [93].
The toxicological aspects of the use of melibiose are less studied. It does not
have regulatory approval for use as an additive in food or drug products.
However, melibiose occurs naturally in food products consumed by humans,
including honey, cacao and soy beans [94-96]. It has also been described as a
hydrophilic skin permeation enhancing agent in topical cosmetic formulations
[97]. No hazard notifications are associated with melibiose in the European
Chemicals Agency (ECHA) substance information database [98].
Melibiose is indigestible by humans, and the consumption of large doses
can have laxative effects, similar to other indigestible sugars. For this reason
melibiose has been used in intestinal permeability tests, where 5 g melibiose
doses have been orally administered to paediatric patients [99]. In this test,
the detection of melibiose in urine is a sign of decreased intestinal integrity
(bowel disease), but the test itself was not reported to have toxic effects.
On the other hand, gut microbes can metabolise melibiose. Dietary
melibiose has been proposed to act as a prebiotic and modulate the intestinal
flora by supporting the growth of lactic bacteria (particularly bifidobacteria),
thereby possibly acting towards inhibition or alleviation of allergic symptoms.
Induction of immunological tolerance to orally administered antigens by
dietary melibiose has been demonstrated in mice [100].
Data on the safety of parenteral administration of melibiose is limited. The
pharmacokinetics of melibiose has been studied in rats, where melibiose was
administered intraveneously as a single bolus dose (100 mg/kg), without
reported side effects [101]. Melibiose has also been administered to mice as
intraperitoneal injection for consecutive 7 days (24 mg/kg/day) [102]. In this
study by Lee et al. 2015, melibiose was shown to have similar autophagy-
inducing and polyQ aggregation inhibiting activities as trehalose, and was
proposed to have potential pharmaceutical use in polyQ-mediated
neurodegenerative disease treatment. No toxicological effects were reported.
Conclusive toxicological studies would be needed to prove that a new
excipient is safe for human use in pharmaceutical products. Such studies
would be very expensive. To ensure that the tests would be worth conducting,
it would be useful to have strong proof that a new excipient provides
advantages over the current selection of already approved excipients.
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2.3 Spray drying
Spray drying is a process that converts solutions or suspensions to powders
composed of microparticles. Development of the technology was driven by
World War II, when huge amounts of food needed to be transported, which
created requirements for better conservation and reduction of the weight and
volume of the food products [103]. Today, spray drying is a widely used
technology in various fields of industry, including the pharmaceutical industry
[104, 105].
The main advantages compared to other drying techniques (including
lyophilisation) are the short process cycle time, scalability, possible energy
savings, and the ability to engineer particles with different physical properties
by controlling the process variables [106-108]. Spray drying enables 1) the
manufacturing of particles in the size range of 1-100 μm mean particle
diameter with a narrow size distribution, 2) very fast solvent evaporation to
produce amorphous solids, 3) control of the drying rate to adjust particle
properties e.g. solid state form, particle size, morphology, density and 4)
control of the surface composition.
As a result, there are several applications in pharmaceutical technology
including production of amorphous excipients and active ingredients to
improve their properties (e.g. lactose with better compressibility; improved
solubility and bioavailability APIs), particles for pulmonary and nasal delivery,
modified-release particles (via microencapsulation) as well as dried
biopharmaceutical products and vaccines [4, 104, 106, 108-110].
2.3.1 The spray drying process
The underlying principle of spray drying is simple: a feed liquid is atomised
into fine droplets, which are immediately exposed to a heated gas stream. The
very large surface area of the atomised droplets allows efficient heat transfer
from the drying gas to the liquid. The solvent evaporates rapidly and solid
matter precipitates to form particles, which are then separated from the air
stream and collected as the dried product [4, 103, 108]. Different designs are
available for atomising the liquid stream (e.g. rotary atomisers and pneumatic
[gas-assisted], hydraulic [high-pressure] or ultrasonic nozzles), powder
collection (e.g. cyclones or bag filters), and mass flows in the drier (orientation
of the atomiser in relation to the drying gas flow: co-current, counter-current,
or mixed flow). A schematic of a co-current spray-drier with a two-fluid
pneumatic nozzle atomiser and a cyclone is shown in FIG 5.
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Figure 5 Schematic diagram of a spray drying process.
Despite the superficially simple principle, spray drying has also been described
one of the most complicated types of drying [103]. There are several process
variables, of which the operator can directly influence only some, including the
inlet temperature of the drying gas (Tinlet), the drying gas flow rate, the liquid
feed rate and the atomisation rate. The other process parameters that affect
the process outcome, including the outlet temperature of the drying gas
(Toutlet), the droplet size, the drying efficiency and the physical properties of
the dried particles (e.g. particle size, moisture content, hygroscopicity), cannot
be directly set but are dependent on the mutual relationships of the
parameters adjusted by the operator, environmental conditions and material
properties. The complex network of some factors affecting the spray drying
process in shown in FIG 6.
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The factors affect the final powder properties through influencing the drying
of the droplets and particle formation [4, 112-115]. The drying stages of a
droplet can be divided into initial, constant and falling rate periods, during
which the droplet temperature changes (FIG  7). During the initial period,
solvent evaporation is rapid and mainly controlled by the relative humidity,
temperature and velocity of the drying gas surrounding the droplet. The
droplet surface temperature increases to the lowest temperature that allows
solvent evaporation, and the surface maintains 100% relative humidity (at the
droplet surface and surrounding vapour cloud temperature which are equal).
Figure 7 A typical drying curve, showing the different drying stages, the temperature of
drying air, and the temperature and moisture content of the drying droplets. The drying curve
is very much dependent on feed composition and process parameters. Modified from Haque and
Adhikari 2015, and Singh and Van den Mooter 2016 [113, 116].
By the constant rate period, a concentration gradient has formed due to the
solvent evaporation from the droplet surface. This initiates diffusion of the
droplet components: the solutes migrate from the highly concentrated exterior
towards the core of the droplet and the solvent moves outward.
Simultaneously, evaporation occurs, which results in both evaporative cooling
(keeping the droplet temperature constant) as well as shrinking of the droplet,
as the surface recedes towards the centre. The solute usually diffuses slower
than the solvent, resulting in increasing viscosity at the surface which further
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restricts all diffusion, and ultimately the solute concentration reaches the
solubility limit and solidification begins. By the end of this period, a solid shell
or crust has formed around the still wet interior.
During the falling rate period, the evaporation rate falls because of the
suppressed diffusion of water through the growing shell on the surface, and
the droplet temperature begins to increase. However, even at the final drying
stage, the product temperature never reaches the Tinlet but in practice remains
below the Toutlet [4, 103].
The final particle shape and moisture content depend on the drying rate
and the diffusion coefficient of the solutes, as well as the crust properties, such
as permeability. When the diffusion of the solutes is faster than evaporation
and surface recession, dense, solid particles with uniform composition may be
formed. In contrast, when the diffusion of the solutes is slower than
evaporation (i.e. with larger molecules and/or fast drying rates), surface
enrichment occurs earlier, which can lead to the formation of either hollow
spherical or irregular (e.g. folded, wrinkled) particles, depending on the
rigidity and porosity of the formed shell. In case there are different solute
molecules in the feed, separation of the components is possible, resulting in
multi-layered particles. Relationships between process parameters and
resulting particle properties are listed in Table 4.
Table 4. The effect of spray drying process parameters on particle properties with solid
dispersions. Modified from Vasconcelos et al. 2016 [11].
Parameter (increase) Particle
size
Particle
porosity
Particle
moisture
Particle
smoothness
Powder
yield
Tinlet Increase Decrease Decrease Decrease Increase
Drying flow rate Decrease Increase Decrease Increase Increase
Feed rate Decrease Decrease Increase Increase Decrease
Humidity Increase Increase Increase Decrease Increase
Increase in droplet size Increase Increase Increase Decrease Increase
Solid content in feed liquid Increase Decrease Decrease Decrease Increase
Solution viscosity or
surface tension
Increase Decrease Increase Decrease Increase
2.3.2 Spray-dried proteins
Lyophilisation is the standard drying technology with protein formulations,
but spray drying is increasingly used in the biopharmaceutical industry [4,
108]. There are numerous examples of spray-dried proteins and polypeptides,
e.g. insulin, haemoglobin, albumin, ǃ-galactosidase, lactate dehydrogenase,
trypsin, tissue-type plasminogen activator, monoclonal antibodies, growth
hormone, calcitonin, parathyroid hormone, and rhDNase, excellently
reviewed in Searles and Mohan 2010 [106]. There have been at least two
commercial spray-dried insulin powders for inhalation (Exubera and Afrezza),
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as well as a thrombin-fibrinogen powder (Raplixa) for controlling bleeding
during surgery [117-120].
Spray drying is an attractive alternative to lyophilisation because of the
general reasons mentioned above, including the process being faster and more
scalable, as well as allowing control of particle properties and direct particle
generation in a single unit operation. These advantages makes the technology
much more suitable for production of products for pulmonary or nasal
delivery. However, spray drying may also provide better stabilisation with
some proteins, since the freezing step and the related risks of protein
degradation (caused by ice surfaces, formulation component crystallisation
and phase separation) is avoided. In addition to final dosage form production,
spray drying is also an alternative for bulk intermediate production for
storage, which is traditionally done by freezing, offering convenience for
transportation and time savings since the thawing step following freezing is
avoided [121]. Spray dried bulk intermediates would also allow admixing with
other powders to obtain the final drug product, without the complexity of
designing a liquid formulation for multi-dose products or the additional freeze
drying step [106].
Spray drying poses several stresses to proteins, however. These include
elevated temperatures, shear stresses, air-water surfaces and drying. Of these,
heat stress can be negligible with many proteins since the drying temperature
is adjustable, the time-scale of heat exposure can be short and the product
temperature may remain relatively low because of the efficient evaporative
cooling [4, 104]. The interfacial stresses can be significant because of the very
large surface area of the atomised droplets. Drying is another major instability
factor. Therefore, protein-stabilising excipients are usually required.
There are occasional examples where proteins have been successfully
spray-dried without excipients, e.g. insulin [122] and crystallised trypsin [123],
however, excipients are usually essential to protect the protein from the spray
drying stresses. Both sucrose and trehalose are commonly used [6, 7, 124-130],
and out of these trehalose has become the standard as the carbohydrate
protein stabiliser with spray drying [121].
For efficient stabilisation, the protein and excipient must remain in the
same amorphous phase. There is a risk of separation of the low-molecular-
weight excipients from the high-molecular-weight proteins as a result of the
particle formation process [107]. Proteins tend to accumulate on the drying
particle surfaces since they have lower diffusion coefficients than the other
components, and they may additionally be surface active, a quality shared by
many proteins. It may happen that in the final product there is a large fraction
of protein at the dry particle surface, not encapsulated in the sugar matrix
[112]. Surface activity is very protein-dependent and the solute separation may
be controlled by adjusting the drying rate (slower rates result in more even
distributions).
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2.4 Raman spectroscopy for solid-state analysis
2.4.1 Raman spectroscopy
Raman spectroscopy involves illuminating a sample with monochromatic
laser light and detecting the inelastically scattered photons [131]. These
Raman scattered photons have different energies compared to the single-
frequency light source, because of energy exchange between the sample
molecules and the incident photons, resulting in a series of Raman shifts which
are dependent on the molecular vibrations (e.g. stretching or bending of
chemical bonds) and rotations occurring in the sample. Therefore Raman
spectroscopy is a vibrational spectroscopy technique and it gives information
on the functional groups present and their chemical environments, dictated by
the molecular conformation and interactions with neighbouring molecules.
This allows both identifying the analytes, as well as distinguishing different
solid-state forms of the same chemical entity [17].
When light interacts with matter, Raman scattering is a very unlikely event
[131]. The great majority of the incident photons that scatter from the sample
will not exchange energy with the molecules. This elastically scattered light is
called Rayleigh scattering, and it needs to be efficiently removed in order to
observe the intrinsically weak Raman signal. In Raman spectrometers this is
achieved by laser rejection filters. The filters only allow light that has a
different frequency than the laser to be detected, and enables the observation
of the Raman spectrum, containing the informative Raman bands (FIG 8).
Usually, Raman spectra represent the Stokes Raman scattered photons, which
have transferred energy to the molecules. In most situations, there are
symmetric but much less intense bands on the other side of the laser line,
caused  by  opposite  energy  transfer  which  is  a  very  rare  event  in  normal
conditions, called anti-Stokes Raman scattering.
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Figure 8 Energy levels associated with Stokes Raman scattering and fluorescence, and the
corresponding signals. In the example a fluorescent sample is illuminated with either 514.5 nm or
785 nm light. The energy and intensity axes are not to scale, and the fluorescence intensity is
several orders of magnitude greater than Raman scattering. Raman shifts appear at the same
position irrespective of the incident light wavelength (always 0 cm-1). ǌ is the vibrational quantum
number. Modified from McCreery 2000 [131, 132].
Another phenomenon that can occur upon photon interaction with molecules,
which can complicate the detection of the Raman signal, is fluorescence.
Fluorescence involves photon absorption and transition of the molecule to an
electronically excited state, and subsequent vibrational relaxation and
emission. It may occur when the energy of the incident photon corresponds to
the energy gap between the ground state and an excited electronic state of the
molecule, and therefore it is dependent on the laser wavelength and the
molecular structure of the analyte. When fluorescence appears, it can leave the
Raman bands fully undetectable, since it is a stronger event (FIG 8).
Assuming negligible absorption and additional scattering interactions of
the Raman scattered photons with the analyte, Raman scattering intensity is
directly proportional to the number of molecules sampled, giving the basis for
quantitative Raman analysis [17]. The intensity of a Raman band is also
dependent on the change in the electronic polarisability of the molecule during
the vibrational mode [131]. When the electron density distribution
surrounding a molecule or a bond is easily distorted during a vibration, large
polarisation changes occur and strong Raman bands may be observed. This
selection rule for Raman activity results in Raman and infrared (IR)
spectroscopy being complimentary techniques. Symmetric vibrations, non-
polar bonds and molecules with extended Ⱥ systems (delocalised electron
systems, e.g. conjugated aromatic rings) can give strong Raman scattering (but
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weak IR absorption, since IR requires a dipole moment change), while
asymmetric vibrations and polar bonds (e.g. O-H) give weak Raman scattering
(but strong IR signals). This is convenient for pharmaceutical analysis, since
many active pharmaceutical ingredients (API) contain aromatic conjugated
rings and give strong Raman signals, while water and many excipients are
weak Raman scatterers [14]. Therefore, Raman signals of the API can often be
collected without significant interference from excipients or aqueous
environments. Some other advantages and disadvantages of Raman
spectroscopy compared to other analytical techniques are listed in Table 1.
The versatility of Raman spectroscopy has resulted in its wide use in the
pharmaceutical industry covering various analytical needs from the early drug
discovery and development phases, through product manufacturing to quality
control of finished products [13]. Some applications include solid form
screening, API degradation analysis in different conditions, monitoring
fermentation or crystallisation processes, raw material qualification,
investigating the distribution of components e.g. in solid dispersions or
lyophilisates, getting insight to drug dissolution behaviour or transportation
to target tissues, content analysis of packaged products and counterfeit
identification [13, 132].
A major application area is the detection and monitoring of solid-state
transformations, which is routinely used in pharmaceutical manufacturing
and quality control [30]. Polymorph conversions, transitions between solvated
and non-solvated forms, amorphisation and recrystallisation of amorphous
systems can all be evaluated [30].
The combination of the advantages of Raman spectroscopy (e.g. non-
destructive, non-contact and fast measurements) makes the technique very
suitable for monitoring the production of pharmaceutical solid dosage forms,
and it is widely used as a PAT tool [36, 133]. Examples of in-process monitored
events during unit operations include: blend homogeneity during blending,
hydrate formation during granulation, phase transformations during drying,
determining coat thickness and composition during tablet coating, solid state
changes during pelletisation, and solid state conversions and process phase
endpoint detection during freeze-drying [133]. Real-time monitoring and
control of continuous pharmaceutical production processes are a major
interest within the pharmaceutical industry [133]. Monitoring transitions
requires reliable quantitative analysis of the collected spectral data. The
inherent disadvantages of Raman spectroscopy, namely low sensitivity and
fluorescence interference, may negatively impact the quality of such analyses.
2.4.2 Low-frequency Raman spectroscopy
The vibrations observable by Raman spectroscopy are not limited to
intramolecular bond vibrations, intermolecular vibrations also occur. The
latter are known as lattice vibrations or phonon modes in crystalline solids,
and they are caused by many atoms or molecules in a crystal oscillating
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coherently at the same frequency [15]. Lattice vibrations are directly related to
the long range order and can be used to probe the solid-state structure of
materials [134]. Different crystalline forms have distinct phonon spectra with
sharp features corresponding to the lattice vibrations, while amorphous solids
have no phonon peaks and only show an inhomogeneous broadening of
features, sometimes called the Boson peak, similar to XRPD [134, 135]. The
lattice vibrations have low energy, with small shifts from the laser frequency
at the terahertz frequency region (below 100 cm-1), in contrast with the
intramolecular vibrations, which appear in the mid-frequency spectral region
(usually between 500-2000 cm-1) [14]. Raman scattering analysis of the low-
frequency vibrations is therefore called low-frequency or terahertz Raman
spectroscopy.
With conventional dispersive Raman instruments, the low-frequency shifts
are normally blocked by the laser rejection filters together with the Rayleigh
scattering. Spectrometers differ significantly in their ability to detect Raman
shifts below 300 cm-1 [131]. The best notch filters today may allow spectral
collection down to 50 cm-1 [13], but generally spectral data below 150 cm-1 is
not observed with a standard Raman instrument [136]. Nevertheless, the
detection of the full low frequency spectrum requires more sophisticated
instrumentation compared to the established technology. Recent
technological advancements, particularly related to volumetric holographic
grating notch filters, stable diode lasers and amplified spontaneous emission
suppression filters [137, 138], have made low-frequency Raman spectroscopy
more practical and widely accessible than in previous decades.
Driven by these technical advancements, commercial and affordable low-
frequency instruments have lately become available, which has made the
technique attractive for pharmaceutical research applications [139]. Low-
frequency Raman spectroscopy has been used for different solid-state
analytical purposes, including identification of drug and excipient polymorphs
and polymorph screening [15, 140-143], tablet composition analysis [144],
evaluating crystallisation of amorphous systems [134, 136, 145, 146] and other
solid-state changes [145, 147-150].
Despite such studies demonstrating the feasibility of low-frequency Raman
spectroscopy for solid-state analysis, including quantitative applications [134,
136, 145, 147], low-frequency Raman spectroscopy is not yet a routine
technique in pharmaceutical solid state analysis. Instead, the conventional
instruments and mid-frequency region is normally used. Solid-state forms can
often be distinguished and quantified using this spectral region dominated by
intramolecular vibrations, because of the changes in local environments of the
bonds within the molecules [17]. Still, this provides only an indirect measure
of solid-state structure, and with some materials the mid-frequency spectral
differences between solid-state forms are very subtle or even completely
indistinguishable [141, 142, 145, 147, 149, 151]. Since low-frequency Raman
spectroscopy measures the fundamental intermolecular modes, it is much
more sensitive to intermolecular interactions [135]. However, studies directly
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comparing the use of these two spectral regions for analytical purposes are
limited, and it has not yet been thoroughly demonstrated that the additional
spectral information obtainable by low-frequency Raman spectroscopy would
provide additional value for routine solid-state quantification purposes.
2.4.3 Time-gated Raman spectroscopy
The elevated background signal induced by sample photoluminescence such
as fluorescence (FIG 8) can inhibit or affect the reliability of analysis based on
Raman bands, and restrict the use of Raman spectroscopy in applications
involving fluorescent or otherwise photoluminescent materials. There are
numerous methods that can be used to reduce the effect of fluorescence,
including photobleaching, the use of longer excitation wavelengths (near-
infrared 1064 or 785 nm lasers), frequency-domain methods (phase-
modulation), shifted excitation Raman difference spectroscopy (SERDS),
surface-enhanced Raman spectroscopy (SERS), nonlinear techniques e.g.
coherent anti-Stokes Raman spectroscopy (CARS) or stimulated Raman
spectroscopy (SRS), spatially offset Raman spectroscopy (SORS, [152]),
computational methods (i.e. fluorescence removal by spectral processing), and
time-resolved Raman spectroscopy [153].
Time-resolved methods rely on the different average lifetimes of
Raman-scattered and fluorescence photons (FIG 9) [154]. Raman scattering
occurs practically instantaneously during excitation, while the lifetimes of
fluorescence signals are generally significantly longer [16]. This is because
fluorescence involves a number of events: the absorption of one or more
protons to excite the molecule to an electronic excited state, followed by
internal conversions which can include various molecular changes at different
time scales, before de-excitation and emission of the fluorescent photons
[155]. The average time required for completion of all these events is
considerably longer (typically in the nanosecond range from excitation) than
for Raman scattering (in the picosecond range) [155]. With conventional
Raman instruments, all these photons will contribute to the spectrum.
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Figure 9 The principle of time-gated Raman spectroscopy. By synchronising the laser pulse
and the time gate it is possible to reject a significant proportion of the fluorescence photons. The
curves represent the probability distributions of the photons. Modified from Nissinen et al., 2017
[154].
In contrast, time-resolved measurements exploit this lifetime difference by
using short laser pulses (instead of the continuous wave excitation used in
conventional instruments) and synchronised temporally resolved detection. If
the signal is only recorded during the laser pulses, it is possible to exclude the
portion of the fluorescence photons emitted after the Raman scattered
photons and collect Raman spectra with minimised fluorescence contribution
(FIG  9) [16, 153, 156]. Different techniques can be used to achieve time-
resolved measurements, e.g. based on optical Kerr gating or fast time-gated
detectors, which may be photomultiplier tubes, intensified charge-coupled
device cameras (iCCDs), streak cameras and complementary metal oxide
semiconductor (CMOS) detectors [153].
Time-gated Raman spectrometers based on CMOS single photon avalanche
diode (SPAD) detectors have recently become commercially available. The
operational principle is based on the laser pulse simultaneously illuminating
the sample and triggering a delay generator enabling the SPAD operation, thus
allowing synchronisation, as well as controlled delays, between the laser pulse
and photon detection, [156-158]. The use of these detectors allows more
affordable and compact instruments compared to those relying on other
detector technologies [154]. Since these instruments also allow measurements
in ambient light and at elevated temperature because thermal interference is
avoided, they are potentially suitable for in-line measurements in process
settings. This makes the technology appealing also for pharmaceutical process
monitoring purposes.
The feasibility of such time-gated Raman spectroscopy measurements
using a picosecond pulsed laser and a CMOS SPAD detector for qualitative
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solid state analysis of pharmaceuticals has been demonstrated [159]. However,
the applicability of the technology for quantitative analysis of solid-state form
mixtures, and thus potential for solid-state transition monitoring has not been
evaluated previously.
2.5 Multivariate data analysis
The data collected by Raman spectroscopy may contain spectral variation
which is important, but subtle and difficult to observe visually [30, 37].
Analyses are generally much more reliable when using spectral windows
containing many Raman bands, compared to methods relying on a single band
[17]. Furthermore, the amount of spectral data increases when the signals are
composed of more dimensions, as is with time-gated Raman spectroscopy and
the additional time domain. Very large datasets are also produced in process
monitoring applications [13]. Similarly, the complex relationships between the
multiple spray drying process parameters and their interdependencies with
the various properties of spray dried powders (FIG  6) may be difficult to
identify by evaluating individual parameters. The complex and large datasets
require sophisticated data analysis approaches which can deal with large data
matrices and reliably identify significant variation. Such analysis involving
multiple variables is called multivariate data analysis.
There are various multivariate methods, out of which principal component
analysis (PCA) and partial least squares (PLS) regression are some of the most
often applied multivariate tools in the chemistry and technology fields, also in
pharmaceutical research [17, 37, 160, 161]. They allow identification and
quantification of systematic variation and correlations in data sets.
PCA  is  a  qualitative  method  used  to  display  the  most  significant  and
presumably meaningful data variation while rejecting noise, in order to better
display and potentially classify the data [161]. In PCA, data is arranged in a
data matrix (X), composed of observations (the rows) and variables (the
columns) [162]. The observations can be e.g. analytical samples (different
materials), process time points in a continuous process, batches from a batch
process, or runs from an experimental design. The variables are
measurements that characterise the properties of the observations, such as
spectra or measurements from sensors in a process (e.g. temperature). PCA
transforms the data matrix (X) into scores and loadings matrices, in which the
most significant data variation is represented. The scores can be plotted to
identify e.g. similarities between observations, trends or outliers. In
combination with the loadings, it is possible to identify the specific variables
(e.g. spectral regions or process temperature ranges) responsible for the
similarities or differences between the observations.
PLS is a regression extension of PCA, particularly suitable for modelling
multivariate relationships [160]. It is widely used for quantification of
pharmaceutical solids in mixtures based on spectral data [17]. PLS is also used
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for process modelling, where it can separate the simultaneous influences of
several process variables on a number of product characteristics [163].
PLS relates the data in matrix X (descriptor or predictor variables) to the
additional Y (response variables) matrix by a linear or polynomial multivariate
model [160, 162]. In quantitative analysis, PLS is used for multivariate
calibration. Here, X is composed of a set of spectra (rows) and the intensities
at different wavelengths (columns), while Y contains the concentrations of the
set of samples. PLS is used to create a model that can predict concentrations
from the spectra of new samples. In process monitoring or optimisation, PLS
finds relationships between the variables measured from the process (X), e.g.
at different time points or from the different runs of an experimental design,
and the corresponding values of responses (Y), such as different
characteristics reflecting the quality of the product and yield.
PLS approximates the X and Y spaces by hyper-planes, i.e. high-
dimensional spaces, and creates new variables (t for the combinations of the
original X variables using weights w, andu for the combinations of Y variables
with weights c) independently for both X and Y matrices (FIG 10). Next, PLS
analysis maximises the covariance between X and Y (u and t) by a linear or
polynomial model.
Figure 10 PLS principle. In PLS, PCA is first performed for both the X and the Y variables. The
best correlation between X and Y is then calculated using the least squares technique. Modified
from Gabrielsson et al., 2002 [161].
PLS can deal with numerous responses simultaneously, allowing fast analysis
of massive datasets, and gives an overview of the relationship between the
responses and all the variables that affect all the responses. Compared to
traditional regression, PLS models the structures of the matrices, and is able
to analyse data with many, noisy or collinear variables [160]. It can be used for
very many data analysis problems, explaining its popularity.
However, there are also other multivariate analytical methods. Kernel
based regularised least squares (RLS) is a well-established method in the
machine learning literature [18, 164], but no so in the pharmaceutical field.
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Similar  to  PLS  and  PCA,  RLS methods  can  be  used  to  solve  regression  and
classification problems with complex data. Here, a least squares cost function
is coupled with a kernel function as data similarity measure to solve the
problem. Kernel functions are a powerful way to infer nonlinear predictors
using linear algorithms such as RLS. Similar to PLS, the variables are spread
into hyper-spaces [18]. Kernel-based RLS uses kernels, such as Gaussian
radial basis functions, to find the best fitting surfaces in the high dimensional
feature space [18]. There are a number of well-known similarity kernel
functions, of which the Gaussian function is widely used, and the choice of the
kernel is not limited to linear and polynomial functions like with PLS. RLS is
however simultaneously designed to prevent overfitting, with a preference for
less complicated models. The solutions of the kernel-based RLS are restricted
by regularisation, which is applied to prevent overfitting and guarantee the
model smoothness, with a preference for less complicated models by
penalizing the solution to prevent increased complexity of the final model.
When using multivariate analysis with spectral data, for example for a
quantification problem, some spectral preprocessing is normally needed.
Normalisation methods, such as standard normal variate (SNV)
transformation can correct for uninformative spectral differences, e.g.
variation in sample focusing or laser power [165]. SNV and mean centering are
established spectral pretreatment algorithms with quantitative analysis [166,
167]. Computational baseline correction methods are often used when the
spectra contain elevated baselines, due to photoluminescence.
For quantitative analysis, measures are needed to evaluate the quality of
the quantitative model. Commonly used are root-mean squared error of
prediction (RMSEP) and root-mean squared error of cross validation
(RMSECV). Both are calculated based on the differences between the values
predicted by the model and the true values using Equation (1).
(1) ܴܯܵܧܲ =  ටσ (௬ିþ)మ೙೔సభ ௡     ,
where y is the true value, ? is  the  predicted  value  and n is  the  number  of
observations. The difference is that for RMSEP the predicted values are
obtained from an independent test set, completely separate from the set used
for model calibration. For RMSECV, cross validation is used, where one or
more samples are removed from the calibration set. The model is built using
the remaining samples and the removed sample(s) is/are used to calculate the
error using Equation 1. Next the sample(s) is/are returned to the calibration
set, and a new sample (group) is removed, and the process is repeated. At the
end  of  this  iterative  process,  all  samples  have  been  used  for  both  model
calibration and calculating the error.
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3 Aims of the study
The overall aim of this thesis was to evaluate strategies for controlling stability
and monitoring solid-state forms in pharmaceutical powders. The goals were
to identify new stabilising excipients for spray-dried protein formulations and
Raman spectroscopy-based methods for solid-state analysis in the
pharmaceutical field.
The specific objectives were:
 to study the spray drying process behaviour and physical stability of
amorphous isomalt and melibiose powders, in order to assess their
potential as new protein-stabilising excipients for spray-dried
formulations (I)
 to evaluate the stabilising efficacy and process behaviour of melibiose
in spray-dried protein formulations in comparison to the standard
excipient, trehalose (II)
 to investigate low-frequency Raman spectroscopy for quantitative
analysis of solid-state form mixtures (III)
 to test time-gated Raman spectroscopy for quantitative solid-state
analysis of fluorescent pharmaceutical powders (IV).
Experimental
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4 Experimental
4.1 Materials (I-IV)
The molecular structures of the two potential new excipients for spray-dried
formulations, melibiose and isomalt, that were compared with trehalose and
sucrose  in  (I), are presented in FIG  4. With the spray-dried protein
formulations in (II), the protein-stabilising efficacies of formulations
containing either melibiose or trehalose were additionally compared to
reference formulations containing maltodextrin or erythritol, to evaluate the
general stabilising effect of the disaccharides in regards with other types of
molecules. Maltodextrin was an example of a higher-molecular weight
compound, compared to the studied disaccharides, which produces
amorphous powders with a high Tg (approx. 150 °C). Erythritol was an
example of a carbohydrate compound, with a closer molecular weight to the
studied disaccharides, but a low Tg (approx. -42 °C) and higher propensity to
crystallise.
To investigate the Raman spectroscopy methods for quantitative analysis
of solid-state form mixtures in (III)  and (IV),  the drug piroxicam was used
(FIG 11). Piroxicam was selected as a model drug, because it has several solid-
state forms that can commonly occur in industrial processing or storage
situations. It also has low aqueous solubility and high permeability (belongs in
the Biopharmaceutics Classification System class II), and therefore the solid-
state form potentially matters therapeutically. Piroxicam also exhibits
photoluminescence (fluorescence). The details of the studied materials are
presented in Table 5.
Figure 11 The molecular structure of piroxicam.
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Table 5. The materials used in the studies.
Name Purpose Description Mol.
weight
Trade name or
code / supplier
Publi-
cation
Melibiose A potential new
stabilising excipient
Disaccharide 342.3 M5500 / Sigma-
Aldrich
I-II
Isomalt A potential new
stabilising excipient
Disaccharide-based
alcohol, GPM-GPS
ratio 1:1
344.3 GalenIQ 720 /
BENEO-
Palatinit
I
Trehalose Standard protein-
stabilising excipient
Disaccharide 342.3 T9531 / Sigma-
Aldrich
I-II
Sucrose Standard protein-
stabilising excipient
Disaccharide 342.3 84097 / Sigma-
Aldrich
I
Maltodextrin Excipient for a
reference formulation
(example of a high
MW and Tg
carbohydrate)
Glucose polymer
(hydrolyzed starch),
with dextrose
equivalent 18
~1000
(average
polymer
size)
Maltrin M180 /
Grain
Processing
Company
II
Erythritol Excipient for a
reference formulation
(example of a
crystalline, low MW
carbohydrate)
Mono-saccharide-
based sugar alcohol
112.1 E7500 / Sigma-
Aldrich
II
ȕ-
galactosidase
Model protein Lactase from A.
oryzae; lactose-
hydrolyzing enzyme
~105000 Lactase DS /
Amano Enzyme
II
Piroxicam Model polymorphic
and fluorescent drug
Non-steroidal anti-
inflammatory drug
331.3 USP grade /
Hawkins
III-IV
4.2 Methods
4.2.1 Sample preparation (I-IV)
4.2.1.1 Solutions for spray drying (I-II)
The excipients were dissolved in purified water (at a 10-30% concentration),
to prepare 100 ml solution for each spray drying experiment.
For the protein formulations, the received protein powder was rehydrated,
filtered through a 0.2 μm filter (Acrodisc, Pall Corp, USA), and purified using
desalting columns (PD-10, GE Healthcare, USA). The protein was then mixed
with the 10% excipient solution. The protein concentration was measured
using UV spectrophotometry (A280 nm, UV-1600PC, VWR, China). The final
protein concentrations in the solutions were 0.39 ± 0.04 mg/ml, resulting in
a protein:excipient weight ratio of approximately 1:250.
4.2.1.2 Solid-state form mixtures of piroxicam (III-IV)
Three solid-state forms of piroxicam were used: ǃ anhydrate (Cambridge
Structural Database [CSD]: BIYSEH13 [168], Į2 anhydrate (CSD: BIYSEH06
[169]) and the monohydrate (CSD: CIDYAP02 [168]. The purchased
piroxicam was characterised as form ǃ, and used as received. The Į2 form was
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prepared by dissolving piroxicam in ethanol at 60 °C, and the monohydrate in
water at 80 °C. The solutions were cooled to room temperature and vacuum
filtered to harvest the crystals. Ternary powder mixtures (FIG 12) were
prepared by gently mixing the components and analysed during the same day
to avoid solid-state changes. Fig 12A shows mixtures optimized using special
cubic model experimental design [163], which were used for quantitative
model calibration (III-IV),  as  well  as  for  model  validation  in IV. Fig 12B
shows the independent set of mixtures used for model validation III.
Figure 12 Mixture designs for the piroxicam solid-state form mixtures. A = mixtures for
quantitative model calibration (III-IV), and validation (IV). B = mixtures for cross-validation (III).
4.2.2 Spray drying and storage of the spray-dried powders (I, II)
Spray drying was carried out using a Büchi Mini spray drier B-191 (Büchi
Labortechnik AG, Switzerland), which operated in a co-current mode and was
equipped  with  a  two-fluid  nozzle  (0.7  mm).  Dry  nitrogen  was  used  as  the
atomization gas and the nozzle was connected to a cooling water circulation.
Experimental designs were planned using MODDE (v. 10.1, Umetrics AB,
Sweden). The process parameters that were adjusted included: inlet
temperature (Tinlet), atomization gas flow rate, feed flow rate, feed
concentration and aspirator rate. The aspirator setting (% motor output)
controlled the drying air flow rate, and the volumetric drying air flow rates
corresponding to the chosen aspirator settings were measured using an air
flow meter (Testo 425, Humitec, Finland). The process parameters are
presented in Table 6 (study I) and Table 7 (study II). The reference protein
formulations containing maltodextrin or erythritol (II), were processed using
the mid-point parameters (Tinlet = 160 °C, Atom. = 650 L/h, Asp. = 90%).
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Table 6. Spray drying process parameters for the excipient solutions (I)
Inlet
temperature
(°C)
Atomizing
gas flow
rate (L/h)
Feed
rate
(mL/min)
Feed
concentration
(%)
Aspirator
rate (%)
isomalt 40-100 500-800 1.4-5.5 10-30 50-100
sucrose 40-100 500-800 1.4-5.5 10-30 50-100
melibiose 50-180 500-800 2.7-4.9 10 100
trehalose 100-180 500-800 4.6 10 100
Table 7. Process parameters for the protein formulations with melibiose or trehalose (II).
Inlet
temperature
(°C)
Atomizing
gas flow
rate (L/h)
Feed rate
(mL/min)
Feed
concentration
(%)
Aspirator
rate (%)
melibiose 140-180 500-800 4.8 10 80-100
trehalose 140-180 500-800 4.8 10 80-100
A standard Büchi cyclone separated the powders from the drying air stream,
and the powder that could be recovered from the product collection vessel
attached to the cyclone, and the metallic lid of the collection vessel, was
considered the yield (as percentage of the initial solid mass used to prepare the
feed solution).
The collected powders were transferred into glass vials and taken for
analysis or placed into temperature- and humidity-controlled conditions for
storage stability studies. The excipient powders (I) were stored for three weeks
at two temperature conditions: 25 °C and 40 °C, at 20% relative humidity
(RH). The protein formulations (II) were stored for 30 days at 20 °C and 40
°C, at 18 % RH. The powders were stored in open vials, where the material was
directly exposed to the surrounding humidity.
4.2.3 Powder characterisation techniques (I-IV)
4.2.3.1 Solid-state determination (I-IV)
The solid-state form of the spray-dried samples (I,II) was investigated using
X-ray powder diffractometry (XRPD, Bruker D8 Advance, Bruker Axs Inc,
USA), with CuKĮ radiation (Ǌ=1.54 Å). The samples were scanned over the 5-
40° angular range (2Ǉ) at a rate of 0.05°/s. Differential scanning calorimetry
(DSC 823e, Mettler-Toledo GmbH, Switzerland) was also used, where the
spray dried samples were equilibrated at 25 °C for 3 min and heated to 200 °C
at a 10 °C/min rate with nitrogen as purge gas (50 ml/min). Glass transition
temperatures (Tg) were determined as the midpoints of the transitions and
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melting points as the onset temperatures of the endotherms, using STARe
software (Mettler-Toledo GmbH, Switzerland).
The solid-state forms of the piroxicam samples were determined using
XRPD, DSC and FTIR spectroscopy. The powders in publication III were
measured using a PANalytical X’Pert PRO MPD system (PW3040/60,
PANalytical B.V., The Netherlands), with CuKĮ radiation (Ǌ=1.5 Å) and
scanned from 5Ń to  35Ń (2Ǉ)  with a step size of  0.008Ń (2Ǉ).  The analysis  in
study IV was carried out using a Bruker D8 Advance diffractometer (Bruker,
Germany)  with  a  CuKĮ radiation source  (Ǌ =  1.54 Å)  over  the  5°  -  40°  (2Ǉ)
range with a step size of 0.01°. The solid state forms were confirmed by
comparing the measured diffractograms with calculated diffractograms
obtained from the CSD. With DSC (DSC Q2000, TA instruments in III, and
DSC 823e, Mettler-Toledo in IV), the samples were scanned between 25 and
230 °C, at 10 °C/min, to detect the melting points (onset temperatures).
Possible solid-state changes in the piroxicam powders were also investigated
using FTIR. In III, a Vertex70 (Bruker Optics, Germany) fitted with a
GladiATR diamond ATR accessory (Pike technologies, USA) was used to
record 32 scans over 600-4500 cm-1 with a 2 cm-1 spectral resolution; these
were averaged to obtain the sample spectrum. In IV, a Vertex70 (Bruker
Optics, Germany) with a MIRacle diamond ATR accessory was used for the
measurements, where each sample spectrum was the average of 64 scans over
650-4000 cm-1 with 4 cm-1 spectral resolution.
4.2.3.2 Moisture content analysis (I-II)
The residual moisture contents (total water % w/w) of the spray-dried powders
were measured using volumetric Karl Fischer titration (V30, Mettler Toledo
AG, Switzerland) in (I).  In  (II), the moisture contents of the powders were
determined using the DSC results and water activity measurements (aw). The
aw measurements were carried out using an AquaLab 3 water activity meter
(Decagon Devices, USA), where the water activity was determined at 25 °C and
in triplicate for each sample. The residual moisture content was calculated
based on the measured aw and Tg values, by using the correlation between each
of  these  values  and  the  sample  water  content.  The  average  of  these  two
determinations was recorded as the moisture content. The method was
verified with Karl Fischer titration, and the error was ±0.3%.
4.2.3.3 Particle morphology (I, II, IV)
The particle morphology of the powders was imaged by scanning electron
microscopy (SEM) using a FEI Quanta 250 FEG system (FEI Inc, OR, USA).
The samples were fixed onto carbon tape and sputter-coated with platinum
(Quorum Q150TS, Quorum Technologies, UK). With the spray-dried samples,
the images were used to evaluate the visual appearance and approximate size
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of the particles. With the piroxicam samples, the images were used to
investigate solid-state conversion to the Į2 form and the monohydrate after
preparation, as well as mixing efficiency in the powder mixtures.
4.2.3.4 Protein activity assay (II)
Protein stability during spray drying and storage was evaluated based on
remaining biological activity. The activities were determined by an enzymatic
assay for ǃ-galactosidase (according to Sigma quality control test procedure
11/01 based on [170] and [171]), which is a spectrophotometric o-nitrophenyl-
ǃ-D-galactopyranoside (substrate for ǃ-galactosidase) cleavage rate test. The
activity was measured for each sample after protein purification and mixing
with the excipient solution: this was considered the initial activity and
assigned as 100% relative activity for the corresponding experiment. To
determine the remaining activity after spray drying and storage, the samples
were rehydrated and diluted to the initial concentration. The relative activity
(%) of the processed or stored sample compared to the initial activity was
considered the remaining protein activity. The assay was performed with
duplicate samples, and the measurements before and after spray drying were
performed in parallel.
4.2.4 Raman spectroscopy for quantitative solid-state analysis (III-IV)
4.2.4.1 Low-frequency Raman spectroscopy and reference Raman
measurements (III)
Three Raman spectroscopy instruments were used in (III): two dispersive
instruments with low-frequency capability (LF-785 and LF-830) and one
Fourier-transform Raman spectrometer (FT-1064) as a reference.
The LF-785 was capable of simultaneously recording both low and mid-
frequency spectra. This instrument was used for the direct comparison of low-
frequency and mid-frequency spectral data. It was a home-built system with a
785 nm laser module (Ondax, USA) followed by BragGrate bandpass filters
(OptiGrate, USA) to remove amplified spontaneous emission before
irradiating the sample. Backscattered light from the sample was collected and
filtered through a set of volume Bragg gratings (OptiGrate, USA) and focused
into an LS 785 spectrograph (Princeton instruments, USA) via fibre-optic
cable which dispersed the Raman scattered light onto a PIXIS 100 BR CCD
detector (Princeton instruments, USA). The spectrometer was calibrated using
sulfur and 1,4-bis(2-methylstyryl)benzene. Spectra were collected over -345-
2055 cm-1 with 5-7 cm-1 resolution, and each spectrum was the average of 60
scans each with an integration time of 0.01 s. The focal spot diameter was
~500 μm.
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The LF-830 system was a commercial 830 nm SureBlockTM XLF-CLM
THz-Raman system (Ondax Inc.,  USA).  This instrument was used to collect
high-resolution low-frequency Raman spectra. The sample was arranged in a
180° backscattering geometry relative to a 10x microscope lens. The system
was coupled via a fiber optic cable to an Acton Research SpectraPro 500i with
a slit width of 50 μm. A 1200 grooves mmí1 grating was used to horizontally
disperse the beam on a liquid-nitrogen cooled Spec-10:100B CCD, controlled
by WinSpec/32 software (Roper Scientific, USA). The system was calibrated
using sulfur. Spectra were acquired over the -60 to 430 cm-1 spectral window
with 2 cm-1 resolution. Each sample spectrum was the average of 60 scans each
with an integration time of 1 s. The setup had a focal spot diameter of ~5 μm.
The FT-1064 instrument consisted of a multiRam FT-Raman spectrometer
(Bruker Optik, Germany), 1064 nm Nd:YAG laser and D 418 Ge detector. This
instrument was used to collect high-resolution mid-frequency Raman spectra.
Spectra were collected using OPUS 7.5 (Bruker Optik, Germany) using the
defocusing  lens,  a  laser  power  of  150  mW  and  2  cm-1 resolution with each
spectrum an average of 32 scans. The focal spot diameter was ~2 mm.
With all Raman instruments, three measurements per sample were
recorded. The samples were rotated between replicate measurements to
collect the signal from a new position each time and minimize error due to
possible sample inhomogeneity.
4.2.4.2 Time-gated Raman spectroscopy and reference Raman
measurements (IV)
The time-gated Raman spectroscopy measurements were carried out using a
TG532 M1 Raman spectrometer (TimeGate Instruments, Finland), equipped
with a picosecond pulsed laser (150 ps, 532 nm excitation), a time-gated single
photon counting (CMOS-SPAD) array detector and a sampling probe (BWTek,
USA) allowing measurements in ambient lighting. Sample spectra were
collected over the 700-1700 cm-1 spectral window, and over a 0-5.5 ns delay
time  window  (from  the  laser  pulse)  with  a  step  size  of  50  ps.  The  signal
collection was performed with continuous sample rotation (to reduce the risk
of subsampling), and three replicate spectra were collected for each sample,
each from a new area. The laser spot diameter at the sample surface was ~85
μm, and with the rotation the sampled area was approximately 0.33 mm2. The
spectrometer was calibrated using cyclohexane.
As a reference method for the time-gated Raman analysis (performed with
a  pulsed  laser  operating  at  532  nm  excitation  wavelength),  a  Raman
instrument with the same excitation wavelength but with a conventional
continuous-wave (CW) laser was used. Measurements of the pure piroxicam
solid-state forms were taken to evaluate the fluorescence signal associated
with the different solid-state forms. The reference instrument was a home-
built Raman setup operating in a backscattering geometry and using 532 nm
excitation produced with a CW single frequency laser (Alphalas, Monolas-532-
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100-SM). A 100 x microscope objective (Olympus 100x with 0.70 N.A.) was
used for signal collection, giving a spot size of approximately 0.9 μm
(theoretical minimum spot diameter calculated by d=1.22Ǌ/N.A.). The
scattered light was dispersed in a 0.5 m imaging spectrograph (Acton,
SpectraPro 2500i) using a 600 g/mm grating, and detected with a EMCCD
camera (Andor Newton EM DU971N-BV) at a spectral resolution of 5 - 6 cm-1.
For each sample, a single spectrum was recorded that consisted of the average
of 2 scans, each with an integration time of 5 s. The laser power was ~0.5 mW.
4.2.5 Data analysis and modelling
4.2.5.1 Evaluating spray drying process parameter effects (I-II)
The effect of spray drying process parameters on the powder yields and
characteristics were evaluated with the modelling software MODDE (v. 10.1.,
Umetrics AB, Sweden). Partial least squares (PLS) fitting was used to identify
relationships (covariance) between the process factors and the measured
responses. The models were fitted using only the significant terms
(coefficients), judged by their uncertainty levels (excluding those ranging
across y=0), in order to maximise the predictability (by maximising Q2) and
reduce the risk of overfitting (by minimising the difference between the model
fit R2 and Q2). The statistical significance was confirmed by analysis of
variance (ANOVA), defined at p<0.05.
4.2.5.2 Comparison of low- and mid-frequency Raman spectroscopy
for quantitative analysis (III)
The utility of the low-frequency and mid-frequency spectral regions for
determining solid-state compositions in the mixtures was compared based on
quantitative model performance. Standard spectral processing and
multivariate methods were applied, all carried out with SIMCA software (v.
13.0.3, Umetrics AB, Sweden).
Quantitative PLS regression (PLSR) models were built using different
spectral ranges, recorded with the calibration set samples (FIG 12A). All
spectra were normalised by standard normal variate (SNV) transformation
and mean centering. The performance of the models was determined based on
the ability to predict the contents of the independent test set mixtures (FIG
12B), using the root-mean square error of prediction (RMSEP, equation 1)
as a measure of quantitative capability.
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4.2.5.3 Evaluating time-gated Raman spectroscopy for quantitative
analysis (IV)
With time-gated Raman spectroscopy, quantitative solid-state analysis of the
piroxicam mixtures was performed using two multivariate methods: (1) PLS
regression and (2) kernel-based regularized least-squares (RLS) regression
with greedy feature selection. For both, the used spectral range was 803-1609
cm-1, the spectral data was baseline-corrected using an adaptive iteratively
reweighted penalised least squares (airPLS) algorithm [172] (combined with
local minima fitting for method (1)), and normalised using SNV
transformation and mean centering.
For the PLSR models, the used delay time domain was selected manually,
based on visual appearance. The PLSR models were built and evaluated using
SIMCA software (v. 13.0.3, Umetrics AB, Sweden).
With the kernel-based RLS method, the time domain selection was
performed by an algorithm (RLS algorithm with multi-target greedy feature
selection), which used iterative optimisation to identify the optimal time
domain. The algorithm also selected the most informative Raman shifts and
model hyperparameters (controlling e.g. the risk of overfitting) by nested
cross-validation. The RLS models were based on Gaussian kernel functions,
and they were built and evaluated with the Python-based machine learning
software library RLScore  [164].
The  performance  of  both  the  PLS  and  RLS-based  models  was  evaluated
based on leave-one-out cross-validation, and the used measure of quantitative
capability was the root-mean square error of cross validation (RMSECV).
Here, one piroxicam mixture (all replicate measurements of a mixture in the
calibration set FIG 12A) at a time was not used for model calibration, but as
an unknown sample, for which the prediction error value was calculated
(RMSEP). This was repeated with all mixture samples (n=12), but not the pure
piroxicam solid-state forms. The error values from all cross-validation rounds
were averaged to get the RMSECV of the model.
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5 Results and discussion
5.1 Spray-dried isomalt and melibiose in comparison to
sucrose and trehalose (I)
The suitability of isomalt and melibiose as potential new excipients for spray-
dried protein formulations was tested in comparison to the previously used
excipients sucrose and trehalose. All studied excipients could be spray dried
into amorphous powders, but there were significant differences in the process
behaviour between the materials. Examples of spray drying processes are
presented in Table 8 where the experiments are classified into low,
intermediate or high temperature processes. Production of melibiose powders
was possible at all the temperature classes, while isomalt powders with
acceptable yields could only be produced when low process temperatures were
applied.
Table 8. Spray drying processes with isomalt, sucrose, melibiose or trehalose. The results are
divided into three groups representing process settings at low, intermediate or high process
temperature. Atom. = atomising gas flow rate, Feed. = Liquid feed rate, Asp. = aspirator (drying air
flow rate), M.C. = moisture content, n.d. = not determined due to lack of sample.
Tinlet
(°C)
Atom.
(L/h)
Feed.
(mL/min)
Conc.
(%)
Asp.
(%)
Toutlet
(°C)
Yield
(%)
Tg
(°C)
M.C.
(%)
Low process temperature
isomalt 50 800 1.4 20 100 37 44 42 2.7
sucrose 50 800 1.4 20 100 38 43 34 4.0
melibiose 50 800 4.9 10 100 39 52 47 5.1
Intermediate process temperature
isomalt 100 800 1.4 20 100 73 2 50 n.d.
sucrose 100 800 1.4 20 100 66 26 51 1.9
melibiose 100 800 4.9 10 100 64 15 60 3.6
trehalose 100 800 4.9 10 100 65 36 45 5.5
High process temperature
melibiose 180 800 4.9 10 100 110 27 77 2.0
trehalose 180 800 4.9 10 100 107 64 82 2.6
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5.1.1 Powder yields
Yields above 50% could be obtained with all materials by adjusting the process
settings. Trehalose was the only material that provided such yields at higher
process temperatures. In fact, an increase in yield with increasing drying
temperature was observed for trehalose (Fig 13D). For the other materials,
the highest yields were observed when low process temperatures were used
(FIG 13). The strongest correlation between process temperature and powder
yield was observed with isomalt, where very low yields were obtained when the
outlet temperature was above 50 °C (FIG 13A).
Figure 13 Effect of outlet temperature on powder yields with spray-dried isomalt (A), sucrose
(B), melibiose (C) and trehalose (D).
In addition to temperature, the feed rate had a major impact on isomalt
powder yields. The yields decreased rapidly when increasing the feed rate from
the lowest setting (FIG 14A). The feed rate also influenced sucrose powder
yields, but the effect was not as strong (FIG 14B). For melibiose (FIG 14C)
and  trehalose,  the  feed  rate  did  not  affect  the  yields.  Isomalt  was  the  most
challenging material to spray dry, since not only the process temperature, but
also the feed flow rate needed to be kept at a low setting in order to produce
powders with acceptable yields. Sucrose is known to be a challenging material
to spray dry [173, 174], and isomalt was found to be even more problematic.
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Figure 14 Effect of feed rate on powder yields with spray-dried isomalt (A), sucrose (B) and
melibiose (C).
Both the atomisation gas flow rate and drying air flow rate (aspirator) also
affected the yields. Decreased yields were obtained when the atomisation rate
was  600 L/h or the aspirator setting  75%. With melibiose and trehalose
the atomisation gas flow rate was the main factor affecting the powder yields.
The feed liquid concentration did not affect the yields at the studied level (10-
30%).
Trehalose is known for its good processability during spray drying for a
sugar [124, 175]. Higher process temperatures and feed rates could be used
with trehalose compared to the other studied excipients, and overall the yields
were better. The process behaviour of melibiose was an intermediate between
trehalose and the more challenging excipients sucrose and isomalt. Yields
were lower compared to trehalose, unless the process temperature was low.
The advantage over isomalt and sucrose was that the process parameters could
be more freely adjusted without a significant yield decrease.
5.1.2 Powder characteristics
All produced powders were amorphous, and composed of smooth, spherical
particles. The Tgs and moisture contents of the powders are presented in
Table 9. Powders with the highest Tg values were obtained with trehalose,
followed by melibiose. Isomalt and sucrose powders had the lowest Tg values.
These Tg values reflect the material-specific properties and were also
influenced by the moisture contents of the powders. The process temperature
was the main factor determining the moisture content and Tg. Drying at higher
temperature produced drier powders. When using the same process
parameters, melibiose powders were drier than trehalose powders, and
isomalt powders were drier than sucrose powders.
Table 9. The Tg values and moisture contents of powders resulting from all spray drying
processes which provided sufficient amounts of powders for analyses.
Toutlet (°C) Tg (°C) Moisture content (%)
isomalt 29-73 35-50  2.9
sucrose 30-67 34-63 1.9-4.0
melibiose 39-110 36-77 2.0-5.1
trehalose 58-107 42-82 2.6-5.5
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The difference in the thermal behaviour of the materials partly explains the
variation in the process yields. When the process temperature exceeds the Tg
of the drying material, there is a risk of the material becoming sticky and being
lost from the process stream on contact with the drier walls [175, 176].
Stickiness was a problem particularly with isomalt, which also presented the
lowest Tg values.
5.1.3 Storage stability of the spray-dried powders
All of the powders remained amorphous during storage (three weeks at 40
°C/20% RH), as indicated by their XRPD diffractograms with amorphous
halos and the presence of glass transitions in the DSC curves. However, the
DSC results suggested possible partial crystallinity for isomalt. Furthermore,
changes in particle morphology, with formation of aggregates, were observed
with  isomalt  powders  (FIG 15). No indication of crystallisation or other
physical changes were detected with melibiose powders.
Figure 15 Spray-dried isomalt (A) and melibiose (B) after storage at 40 °C / 20% RH.
The storage conditions used were not according to the International
Conference on Harmonization (ICH) quality guideline Q1A(R2): 25-
30 °C/60% RH, or 40 °C/75% RH for accelerated stability studies [177].
However, according to the ICH protocol, the testing should be conducted with
the material in a container closure system. It is expected that the material
inside a packaging is exposed to a lower humidity than that mentioned in the
guideline, but the exact conditions may remain unknown (dependent on the
package sealing). In the current study, the amorphous powders were stored in
open  vials,  where  the  material  was  directly  exposed  to  the  surrounding
atmosphere and where it was possible to achieve well-defined humidity
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conditions. The selected humidity condition was known to cause stress to such
samples based on previous studies [77]. Regarding the intended use (dried
amorphous biotechnology products), 20% RH can be considered relatively
high in comparison to finished commercial formulations sealed inside
protective packaging.
This was an early study investigating the potential of melibiose and isomalt
for spray-dried formulations. Further studies to investigate the long term and
stress condition stability of formulations containing these excipients are
needed for a more complete understanding of their storage stability, e.g. using
formal stability study protocols, and these should be conducted along with
formulation optimization. It is expected that these types of spray dried
amorphous materials are very sensitive to moisture uptake and a consequent
higher risk of crystallisation. The moisture exposure of such products should
therefore be limited by humidity-protecting containers.
To summarise, this study showed that both melibiose and isomalt could be
spray-dried into amorphous powders by optimising the process parameters.
However, the process behaviour of melibiose made it more suitable for spray
drying processes than isomalt. Compared to trehalose, it was possible to
produce drier powders with melibiose, but the powder yields were lower unless
low process temperatures were used. The physical stability of amorphous
melibiose powders was similar to trehalose and better compared to
amorphous isomalt powders. In conclusion, out of the two potential new
protein-stabilising excipients, isomalt and melibiose, melibiose was selected
as the more promising one for spray-dried formulations.
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5.2 Melibiose as a stabiliser in spray-dried protein
formulations (II)
In this study, the applicability of melibiose as a new protein-stabilising
excipient for spray-dried protein formulations was further evaluated. The
protein-stabilising efficacy during processing and storage, as well as the spray
drying process behaviour and physical stability were compared with trehalose,
which is considered to perform well.
5.2.1 Protein activity stabilisation during spray drying
Both melibiose and trehalose provided protection against protein activity loss
during spray drying. The remaining protein activity after spray drying was
dependent on the process inlet temperature and aspirator (drying air flow)
rate. In contrast, the atomising gas flow rate did not affect protein activity. The
lack of atomising rate effect suggested that the model protein was not sensitive
to mechanical stress. Thus, the observed protein degradation was mainly
temperature-induced, since both the inlet temperature and the aspirator rate
directly influenced the outlet temperature. The Toutlet can be  considered the
maximum process temperature that the product is exposed to [103].
The temperature-dependent activity reduction is shown in FIG 16A. There
was a threshold temperature at 87 °C, below which the protein activities
remained constant, and above which a decline in activities was observed. The
group of experiments falling below this threshold temperature, called here the
lower-temperature group, consisted of experiments with 140-160 °C for inlet
temperature. The other, higher-temperature, group in turn had 180 °C for inlet
temperature. The remaining activities from these two experiment groups are
presented in FIG 16B. In both groups, melibiose was at least equally efficient
in preventing protein activity loss during spray drying as the well-known
stabiliser trehalose.
Figure 16 Remaining protein activities after spray drying as a function of outlet temperature (A)
and the remaining protein activities, grouped based on process temperature. The lower
temperature group (outlet temperature < 87 °C) had an inlet temperature of 140 or 160 °C and the
higher temperature group (outlet temperature > 87 °C) had an inlet temperature of 180 °C.
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Full activity preservation was not observed with either excipient, which is most
likely due to the long process duration (20 min). The product was exposed to
elevated temperature during the entire process time. However, when
comparing to reference formulations, which had either maltodextrin or
erythritol as excipient, the stabilising efficacy of both melibiose and trehalose
was clear. The remaining activity was 40% with maltodextrin and only 3% with
erythritol, while it was 82-89% with melibiose and trehalose dried at the same
process settings. This result is in line with previous studies indicating the
generally better protein-stabilising efficacy of amorphous disaccharides
compared to higher molecular weight polymers (such as maltodextrin) and
crystalline materials (such as erythritol). It can be expected that full protein
activity preservation is possible with melibiose formulations by adjusting the
process settings.
5.2.2 Protein activity stabilisation during storage
Melibiose was able to stabilise the protein activity during storage at least as
well  as  trehalose (FIG 17). The spray-dried formulations could be stored at
+40 °C / 18% RH for 30 days without further activity loss. The recorded
remaining protein activity values trended higher for melibiose formulations
compared to trehalose formulations. The difference was most pronounced
with the samples that had been spray dried and stored at higher temperatures.
This may suggest better stabilisation potential of melibiose, since high
temperatures are stressful to the protein and solid-state stability. However, the
overall difference between the stabilising efficacies of the two excipients was
not statistically significant. These results show that melibiose was at least as
good a protein-stabiliser during storage as trehalose.
Figure 17 Remaining protein activities of the melibiose and trehalose formulations after 30 days
of storage at +20 °C and +40 °C. The observations are divided according to the spray drying
processes, into lower temperature processes (solid colour columns, inlet temperature 140-160 °C,
outlet temperature <87 °C) and higher temperature processes (striped columns, inlet temperature
180 °C, outlet temperature >87 °C).
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5.2.3 Process behaviour and powder properties
5.2.3.1 Powder yields
The powder yields were similar for melibiose and trehalose, and good yields
were possible (70%). The yields of the formulations containing melibiose and
protein were clearly better compared to melibiose spray dried alone (I). With
trehalose, the addition of protein in the formulation did not have an effect on
powder yields.
Trehalose yields were mainly determined by the atomizing gas flow rate
(FIG 18A). Melibiose yields were influenced by both the atomizing rate (FIG
18A)  and  process  temperature  (FIG 18B). The best powder yields were
obtained when using high atomizing rate and lower process temperatures.
Figure 18 Effect of atomising gas flow rate (A) and outlet temperature (B) on powder yields. The
predicted yields when the inlet temperature is constant at 160 °C and the aspirator at 90% (A) and
the observed yields at different outlet temperatures (B).
The aspirator rate did not impact powder yields at the studied range 80-100%.
It is known that drying air flow (aspirator) settings that are too low can reduce
the separation efficiency of the cyclone, leading to lower yields [103]. In the
previous study (I),  it  was  shown  that  a  reduction  in  yields  occurred  upon
decreasing the aspirator setting to 75% or below. The result of this study (II) -
that  a  decrease  in  the  aspirator  setting  down  to  80%  was  possible  without
affecting powder yields - is important because this setting should be
minimized to reduce protein damage.
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5.2.3.2 Powder properties
All of the spray-dried powders were amorphous, as determined by XRPD and
DSC. The Tgs and moisture contents of the melibiose and trehalose
formulations are presented in Table 10. During storage (20 or 40 °C / 18%
RH), the water contents of the powders increased and the Tgs decreased, but
all powders remained amorphous.
Table 10. The Tg values and moisture contents of spray-dried protein formulations containing
melibiose or trehalose. The measurements were performed immediately after spray drying, and
after storage for 30 days at +20 °C or 40 °C, both at 18% RH.
Tg (°C) Moisture content (%)
Before
storage
Storage
+20 °C
Storage
+40 °C
Before
storage
Storage
+20 °C
Storage
+40 °C
Melibiose 69-90 67-88 67-76 1.0-2.0 1.1-2.1 2.0-2.5
Trehalose 68-85 66-85 65-73 2.8-3.2 2.9-3.6 3.5-3.9
The  Tg values were similar between the formulations containing either
melibiose or trehalose (Table 10). Pure anhydrous trehalose has a higher Tg
(~120 °C) than melibiose (~100 °C). The lack of such difference in the Tgs of
the spray-dried formulations is caused by the higher water contents of
trehalose formulations compared to melibiose formulations (Table 10).
Melibiose formulations were generally two-fold and at best three-fold drier
than trehalose formulations when dried at the same process settings. The
atomising gas flow rate affected the moisture contents of trehalose
formulations (a higher rate resulted in drier powder). In contrast, the
melibiose formulations were consistently dry, irrespective of the process
parameters in the studied ranges. This result suggests that more efficient
drying processes are possible when using melibiose as an excipient instead of
trehalose. Furthermore, high residual moisture contents have been mentioned
as a disadvantage of spray drying compared to e.g. lyophilization as a
production method for solid protein formulations [178] . This makes melibiose
a very promising excipient for spray-dried protein formulations.
All of the powders consisted predominantly of smooth, spherical particles
and no morphological changes were observed during storage. The appearance
of the particles was similar between the two excipients, and resembled that of
particles containing pure disaccharide (no protein). The particle morphology
depended on the process settings (FIG 19).
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Figure 19 SEM images of powders spray dried using 140 °C Tinlet / 72-75 °C Toutlet, 500 L/h
atomising gas flow rate, and 80% aspirator rate (low settings) containing ȕ-galactosidase with
melibiose (A) or trehalose (C), and powders spray dried at 180 °C Tinlet / 97-103 °C Toutlet, 800 L/h
atomising gas flow rate, 100% aspirator rate (high settings) with melibiose (B) or trehalose (D). The
scale bar (50 μm) is the same for all images.
As  mentioned  above,  no  crystallization  was  observed  with  any  of  the
formulations  during the  30-day stability  study (at  20 or  40 °C /  18 % RH).
However, during the DSC heat scans, trehalose always crystallised, while
melibiose never did. This difference is related to the possible crystal forms of
the two disaccharides. Trehalose can crystallise to both hydrate or anhydrate
forms. In contrast, water plays a central part in the crystal structures of
melibiose, and only hydrate forms (mono- and dihydrate) have been reported.
The DSC results indicated that in dry conditions melibiose can resist
crystallisation better than trehalose. The highest water content of the
melibiose powders in this work, (2.5% w/w, aw = 0.139), was not sufficient to
allow melibiose crystallisation even during heating. In contrast, trehalose can
crystallise irrespective of the formulation water content, either to a hydrate or
an anhydrate form. Earlier work has also shown that melibiose can be very
stable in the amorphous form and has low molecular mobility compared to
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other disaccharides [81]. It appears possible to produce physically very stable
amorphous protein formulations with melibiose as excipient.
The conducted storage stability studies did not follow the ICH guideline
protocols (12 months at 25-30 °C / 60 % RH and 6 months at 40 °C / 75 % RH)
[177]. More stability studies are needed to investigate the long term and
stressed stability of melibiose-containing formulations. However, the results
from these early studies were promising.
In conclusion, the study showed that melibiose provided protein
stabilisation  during  spray  drying  and  storage  at  least  equally  well  as  the
commonly used excipient trehalose. Melibiose was physically stable in the
amorphous form, and it may resist crystallisation better than trehalose. The
process behaviour with regard to powder yield was similar to trehalose. A
possible advantage for processing and for formulation stability, was that the
spray-dried protein powders with melibiose dried more efficiently to lower
water contents than those with trehalose. Overall, melibiose showed several
promising properties for spray-dried protein formulations.
Results and discussion
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5.3 Low-frequency Raman spectroscopy for quantitative
solid-state form analysis (III)
In this study, the potential benefit of the additional spectral information
provided by low-frequency (terahertz) Raman spectroscopy for standard solid-
state analysis purposes was investigated. The performance of low-frequency
Raman spectroscopy combined with established spectral processing and
multivariate methods in quantifying crystal form mixtures was directly
compared to conventional mid-frequency Raman analysis.
5.3.1 Raman spectra of piroxicam solid-state forms
The pure solid-state forms of piroxicam (ǃ and Į2 anhydrates, and the
monohydrate) showed clear spectral differences in both the low-frequency (8-
200 cm-1) and mid-frequency frequency (700-1700 cm-1) regions (marked by
A and D in FIG 20). There were several unique peaks for each form in both
spectral regions; the positions of several of these are indicated in FIG 20.
Figure 20 Raman spectra of piroxicam solid-state forms (the monohydrate, Į2 anhydrate and ȕ
anhydrate), measured with three Raman instruments (LF-830, LF-785 and FT-1064) recording
different spectral regions. The framed regions show the spectral ranges used for quantitative
analysis: A: 8-200 cm-1, B: -(200-12) cm-1, C: 51-200 cm-1, and D: 700-1700 cm-1. The Raman
peaks specified in the figure present some, but not all, characteristic peaks of each solid-state form.
The solid-state-specific Raman bands observed in the mid-frequency region
(such as 1400, 1543 and 1523 cm-1 in FIG 20) are related to intramolecular
vibrational modes. These vibrations differ mainly because of conformational
differences and because the piroxicam functional groups are differently
involved in intermolecular bonding in the different solid-state forms. Thus the
peak positions give indirect information about the crystalline structures.
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In contrast, in the low-frequency region there are spectral features that are
directly caused by lattice vibrations in the crystalline arrangement. Piroxicam
ǃ and Į2 anhydrates have a similar structure with respect to molecular
configuration, conformation and intramolecular bonding, and they belong to
the same monoclinic crystal system (P21/c). The observed spectral variation in
the low-frequency region is related to the differences in intermolecular
hydrogen bonding, Ⱥ-Ⱥ interactions and molecular packing arrangement
between these forms.
The monohydrate structure differs substantially from the anhydrates,
which is apparent also from the low-frequency spectrum. The monohydrate
belongs to a lower symmetry crystal system (triclinic P1) than the anhydrates.
In addition, in the monohydrate form, piroxicam molecules are present in
substantially different molecular conformations and there are water molecules
in the structure. These molecules are connected to each other by a complex
network of hydrogen bonds and Ⱥ-Ⱥ interactions [168, 179, 180]. The
overlapping spectral features seen with the monohydrate reflect this complex
network.
The most intense peaks with the piroxicam forms were observed below 50
cm-1.  This  spectral  region  is  dominated  by  lattice  vibrations  and  it  is  also
important for differentiating solid-state forms of other drugs (e.g.
carbamazepine) [15].
The LF-785 measurements (the only instrument used in the study that was
able to simultaneously record both spectral regions) showed that the signal
intensities were higher in the low-frequency range than in the mid-frequency
range (FIG 20).  One  reason  for  the  strong  signals  at  low  Raman  shift
frequencies (ߥ෤௝) is that the Raman cross section for a mode jቀడఙೕడஐ ቁ, Equation
2 [181-183], which is related to the observed band intensity, is strongly
dependent on the scattering frequency, ൛ߥ෤଴ െ ߥ෤௝ൟସ, where ߥ෤଴ is the laser
frequency. This is particularly the case in Ⱥ-bonded compounds, such as
piroxicam, because the Raman amplitude, ௝ܵ1, for such transitions is
appreciable:
(2) ቀడఙೕడஐ ቁ = ቀ
ଶరగర
ସହ ቁ ൭
൛ఔ෥బିఔ෥ೕൟర
ଵି௘௫௣൤ష೓೎ഌ෥ೕೖ೅ ൨
൱ ൬ ௛଼గమ௖ఔ෥ೕ൰ ௝ܵ
In Equation 2, T denotes temperature in Kelvin, and the remainder are
physical constants [184].
When the ternary mixtures of piroxicam solid-state forms ǃ, Į2 and
monohydrate were measured, both the low- and mid-frequency spectral
ranges could be used to differentiate the solid-state mixtures from each other
using principal component analysis.
1 The amplitude is related to the derivative terms for the mean (isotropic) polarizability for mode j
(ߙ௝ᇱଶ) and the anisotropy (ߛ௝ᇱଶ) such that ௝ܵ = 45ߙ௝ᇱଶ + 7ߛ௝ᇱଶ [Horvath, Hertzberg].
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5.3.2 Quantitative analysis of solid-state form mixtures: Comparison
of using low- and mid-frequency spectral regions
Quantification of the piroxicam crystal forms in the ternary powder mixtures
was possible using any of the studied spectral ranges, recorded by any of the
instruments used in this study. However, there were differences in
quantitative performance. The results obtained with partial least squares
regression (PLSR) models using different spectral data are shown in Table 11.
The predictive performance of the models are indicated by the RMSEP values.
Table 11. Summary of the PLSR models built using different spectral regions and data
collected with the different instruments. The letters indicating spectral ranges are the same as
in FIG 20. The RMSEE and RMSEP values in the table refer to the averages of the three forms in
the evaluated mixtures. The number of PLSR factors was two for all models. The abbreviations are
explained below the table.
Setup Spectral range (cm-1) Number
of X
variables
R2X R2Y Q2 RMSEE
(%)
RMSEP
(%)
LF-
785a
A 8-200 LF 108 0.974  0.993 0.991 2.6 3.0
B -(200-12) LF (anti-
Stokes)
106 0.981  0.995 0.994 2.1 3.3
C 51-200 LF (partial) 84 0.983  0.976 0.974 4.6 5.0
D 700-1700 MF 557 0.944  0.977 0.974 4.6 5.5
A +
B
8-200 +
-(200-12)
LF (Stokes
and anti-
Stokes)
214 0.977 0.995 0.994 2.1 2.8
A +
D
8-200 +
700-1700
LF and MF 665 0.981  0.997 0.996 1.7 2.9
LF-
830b
A 8-200 LF 528 0.970  0.974 0.964 4.8 5.1
C 51-200 LF (partial) 413 0.977  0.962 0.959 5.8 5.8
FT-
1064c
C 51-200 LF (partial) 156 0.983  0.971 0.968 5.0 5.5
D 700-1700 MF 1038 0.963 0.979 0.976 4.3 4.6
C +
D
51-200 +
700-1700
LF (partial)
and MF
1194 0.963 0.987 0.985 3.4 3.6
a LF-785 spot size ~500 μm, spectral resolution 5-7 cm-1
b LF-830 spot size ~5 μm, spectral resolution 2 cm-1
c FT-1064 spot size ~2 mm, spectral resolution 2 cm-1
LF = low-frequency; MF = mid-frequency; X variables refer to the spectral data points used in the
analysis and they are dependent on the instrument spectral resolution; the coefficients R2X and
R2Y describe the explained fraction of the variation of the variables X (spectral data) and Y (solid-
state form composition); Q2 is the predicted fraction of the variation of the Y variables; RMSEE
describes the fit of the calibration set observations (model fit) and RMSEP measures the model
performance with unknown samples, not used in building the model (predictive power).
The low-frequency spectral region was better for quantitative analysis than the
conventional mid-frequency region. This result was obtained with the LF-785,
which was the only instrument applicable for direct comparison of the full low-
frequency and mid-frequency spectral ranges without confounding sampling
and instrumental variations. The average error in prediction was 3.0% when
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using the low-frequency data (8-200 cm-1)  and  5.5%  when  using  the  mid-
frequency data (700-1700 cm-1). The specific error values for each solid-state
form are shown in FIG 21. Combination of the anti-Stokes spectral data to the
low-frequency Stokes Raman data resulted in a minor further improvement in
quantitative performance.
The other Raman instruments (LF-830 and FT-1064) had different
sampling volumes and spectral resolutions. Therefore, comparison should
take such factors affecting quantitative performance into consideration. The
FT-1064 had the largest spot size, and for this reason the least probability of
error  produced by  sub-sampling,  while  for  the  LF-830 system this  risk  was
highest due to the incorporated 10x objective for focusing. Accordingly, the
FT-1064 performed better in quantification. Nevertheless, the quantification
accuracy of the LF-830 and FT-1064 setups also improved when including
low-frequency spectral data in the analysis.
The results also showed that the very lowest frequency spectral data below
50 cm-1 was highly important for accurate analyses. Developments in Raman
instrumentation has allowed extension of the recorded spectral data down to
relatively low frequency regions also with so-called conventional Raman
instruments (such as the FT-1064 used in this study reaching 50 cm-1). It
appears however, that access below 50 cm-1 provides analytical benefits.
Figure 21 Performance of quantitative solid-state analysis of piroxicam crystal mixtures utilising
different spectral ranges. The results refer to the LF-785 measurements, where the full low-
frequency and mid-frequency spectral data was simultaneously recorded.
Results and discussion
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The reason low-frequency Raman spectroscopy enabled more accurate
quantification of the solid-state form mixtures is likely to be due to the higher
intensity scattering and signal-to-noise ratio. Furthermore, the differences
between the solid-state forms in the low-frequency range are potentially larger
since the vibrational modes are mainly intermolecular in nature and
intrinsically linked to crystal structure. This should contribute to a higher
sensitivity of low-frequency Raman for solid-state forms when compared to
conventional mid-frequency Raman, giving the technique an advantage as a
tool for solid-state analysis.
Piroxicam solid-state forms were readily differentiated using all of the
studied regions of the Raman spectra. However, with other compounds, the
changes in the mid-frequency fingerprint region can be too subtle to allow
differentiation between solid-state forms, in contrast to distinctive solid-state
specific low-frequency bands [141, 142, 145, 147, 149]. For example with
sulfathiazole and phenobarbital, solid-state forms could not be differentiated
by conventional Raman spectroscopy or even by XRPD, while they could be
easily identified by distinct low-frequency Raman spectra [142, 151]. In such
cases the use of low-frequency Raman spectroscopy is expected to have even
more pronounced benefits than it did with the piroxicam mixtures in this
study.
Low-frequency Raman spectroscopy is also a very useful technique with
amorphous materials. Amorphous structures have no distinct lattice
vibrations, therefore there are no peaks in the low-frequency spectral region
originating from such vibrations, and the region is covered by inhomogeneous
broadening instead [134]. This allows immediate differentiation between
crystalline and amorphous materials similar to XRPD, and investigating
crystallisation of amorphous samples. An additional benefit of using low-
frequency Raman spectroscopy in pharmaceutical research is the possibility of
solid-state analysis of active ingredients in the presence of excipients, since
many drug compounds are strong Raman scatterers while many excipients
only produce a weak Raman spectrum, including in the low-frequency range
[14, 15, 150].
In summary, this study showed that the additional spectral data provided
by low-frequency Raman spectroscopy was useful, and it enabled more
accurate quantification of solid-state forms in mixtures than conventional
mid-frequency Raman spectroscopy. This was attributed to the higher
sensitivity for solid-state forms, due to the higher intensity scattering and
signal-to-noise ratio, as well as larger differences between the solid-state
forms in the low-frequency range. Overall, low-frequency Raman spectroscopy
may be better for quantitative solid-state analysis, even in cases where the
solid-state forms can be resolved using conventional mid-frequency Raman
spectroscopy.
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5.4 Time-gated Raman spectroscopy for quantitative
analysis of fluorescent powder mixtures (IV)
In this work, time-gated Raman spectroscopy for quantitative solid-state
analysis of fluorescent powder mixtures was evaluated. Chemometric analysis
of the data consisting of both spectral and time dimensions was performed by
two methods: (1) PLS regression, the most well established multivariate
quantitative analysis method in pharmaceutics, and (2) kernel-based RLS with
greedy feature selection, which optimised data use in both dimensions.
5.4.1 Fluorescence rejection by time-gated Raman spectroscopy
The three  solid-state  forms of  piroxicam (the  ǃ and Į2 anhydrates,  and the
monohydrate) fluoresced to varying degrees when excited by a 532 nm light
source, as represented by the elevated baselines (FIG 22). The ǃ form was
more fluorescent than the Į2 form and the monohydrate. In addition to
fluorescence intensity, also the fluorescence signal lifetime profiles were solid-
state specific. Differences in fluorescence profiles have previously been
observed by time-gated Raman spectroscopy with different solid-state forms
of another drug, the amorphous and Ǆ-crystalline forms of indomethacin
[159].
Results and discussion
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Figure 22 Time-resolved spectra of piroxicam solid-state forms (ȕ and Į2 anhydrates, and the
monohydrate, MH), recorded with the time-gated Raman instrument. The spectra show the
detected photon intensities in the Raman shift dimension (between 800-1600 cm-1) and in the time
dimension (delay from laser pulse between 0-5.5 ns). The raw spectra contain all detected photons,
including Raman scattered and fluorescence photons. The baseline spectra represent the
fluorescence signals. The Raman spectra are the spectra after fluorescence rejection, presenting
mainly Raman scattered photons.
The observed fluorescence baselines were consistent between the time-gated
Raman instrument, utilising a picosecond pulsed laser for excitation, and with
the Raman system equipped with a conventional continuous-wave (CW) 532
nm laser  (FIG 23). This confirmed that the observed fluorescence was not
instrument setup-dependent.
The Raman scattering occurred immediately after the laser pulse (at
approximately 0.4-0.8 ns delay based on visual evaluation), while the gradual
decay of the fluorescence signal was detected over several nanoseconds (FIG
22). By utilising time-gating and selecting only the data recorded in the 0.4-
0.8 ns time-domain, it was possible to reject the fluorescence tail. There was
residual fluorescence which temporally overlapped with the Raman signal,
which was removed by baseline correction. After time-domain selection and
baseline correction, fluorescence-free time-resolved Raman spectra for the
piroxicam crystal forms were obtained (the Raman spectra in FIGs 22 and
23). These spectra clearly showed the characteristic Raman peaks of the
piroxicam solid-state forms [185].
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Figure 23 Spectra of piroxicam solid-state forms (ȕ and Į2 anhydrates, and the monohydrate),
collected by the reference instrument equipped with a continuous-wave laser (CW Raman) and the
time-gated Raman (TG Raman) instrument. The TG Raman instrument spectra are the 2D
(summed) representations of the raw spectra and Raman spectra shown in FIG 22. The TG raw
spectra contain the full temporal signals with fluorescence (‘full time domain’). The TG Raman
spectra are the signals after time-domain selection (0.4-0.8 ns) and fluorescence rejection
(‘selected time domain’). The specified Raman peaks are some, but not all, solid-state
characteristic peaks.
The time-resolved (2D) spectra could be processed and evaluated by standard
spectral processing and multivariate methods (such as PCA and PLS). When
measuring the powders consisting of ternary mixtures of piroxicam solid-state
forms, the mixtures could be differentiated from each other by performing
PCA on the time-resolved Raman spectra.
5.4.2 Quantification of solid-state forms in mixtures
Quantitative analysis was performed using two chemometric methods: (1) PLS
regression and (2) kernel-based RLS regression with greedy feature selection.
For the PLS method, the used time-resolved data which utilised time-domain
selection, was acquired using the 0.4-0.8 ns time-frame, as described above
(5.4.1).  This  time-frame  was  chosen  based  on  visual  inspection  of  the  raw
data.
Results and discussion
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The kernel-based (RLS with greedy feature selection) analysis method was
applied as an alternative approach that optimized the use of the recorded data
in both the temporal and spectral dimensions. The kernel-based algorithm
performed iterative optimisation of the time-domain and Raman shift
selection.
Both methods were applied also with the equivalent of non-time-resolved
spectral data. This data contained the full time domain signal (0-5.5 ns time-
frame) that was baseline-corrected by computational spectral processing. This
situation allowed a direct comparison between time-gated and essentially non-
time-gated Raman measurements, without the complication of experimental
and instrumental differences.
Both chemometric methods showed that determination of the solid-state
composition of the ternary mixtures was possible based on the Raman spectra.
Further, the methods showed that the use of time-resolved spectral data (with
time domain selection) resulted in more accurate quantification compared to
the essentially non-time-resolved (full time domain) data (FIG 24). This
demonstrated that baseline correction for fluorescence signal removal was not
as effective as the instrument-based fluorescence rejection. Baseline-
correction represents a standard spectral processing procedure with
conventional Raman spectroscopy, often performed when spectra have
elevated baselines due to photoluminescence.
Figure 24 Errors in quantification for each piroxicam solid-state form, expressed as RMSECV
(%), when using essentially non-time-resolved, baseline-corrected spectral data (full time domain)
or time-resolved spectral data utilising time frame selection (selected time domain). (1) refers to
the PLS method and (2) is the kernel-based method, with optimisation of data use. The time-frame
refers to the selected signal in the time dimension, used for analysis.
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Using time-resolved data (selected time-domain) with the PLS method
resulted in an average quantification error of 4.1 % for the three solid-state
forms, which was better than the essentially non-time-resolved (full time
domain), baseline-corrected data (6.7 %). The quantitative performance could,
however, be significantly improved by applying the kernel-based method for
optimisation of data use. Three-fold better quantitative performance could be
achieved compared to the PLS method, with an average error of 1.4 %. The
iterative optimisation resulted in a different time-frame compared to the
visually selected one, namely the optimisation resulted in a 0.3-0.6 ns time-
frame instead of 0.4-0.8 ns.
The Raman signals of the piroxicam forms were detected over the
fluorescence backgrounds. However, with other compounds the Raman
scattering can be more completely masked by fluorescence. In such cases time-
gated Raman spectroscopy for fluorescence rejection is expected to offer much
more pronounced benefits than observed in this work. The technique may be
widely applicable in pharmaceutical development and manufacturing, since
not only some active ingredients including proteins, but also many excipients,
such as cellulose-based polymers, fluoresce. Further practical advantages of
Raman spectroscopy are the possibility to focus on the API properties over
excipients in mixtures (in case of drug molecules with aromatic and Ⱥ-bonded
structures), as well as insensitivity to water, and for time-gated Raman
spectroscopy in particular, the possibility to perform measurements in
ambient lighting. These properties make time-gated Raman spectroscopy
particularly suitable for process monitoring applications.
In conclusion, the study showed that time-gated Raman spectroscopy was
applicable for solid-state form quantification and that it provided benefits for
quantitative analysis of fluorescent powder mixtures. The instrument-based
fluorescence rejection allowed better quantification performance compared to
spectral-processing-based baseline-correction procedures. Quantification was
possible with manual time-domain data selection and the standard PLS
regression method, however substantially better results were achieved by data
use optimisation with the kernel-based RLS method with greedy feature
selection. This supports further exploring the possibilities of efficient data use
optimisation and evaluating alternatives for the established data analysis
methods in the pharmaceutical field. Overall, time-gated Raman spectroscopy
was a suitable tool for analysing photoluminescent, including fluorescent,
powders and quantification of solid-state forms in mixtures.
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6 Conclusions
This work was carried out in order to identify possible new stabilising
excipients for spray-dried protein formulations, and to evaluate quantitative
solid-state analysis techniques based on Raman spectroscopy and multivariate
data analysis methods, new in the pharmaceutical field.
By optimizing the process parameters both melibiose and isomalt could be
spray dried into amorphous powders which remained relatively stable (i.e. did
not crystallise). Melibiose showed better process behaviour and physical
stability than isomalt, which made it a more favourable candidate for spray-
dried protein formulations.
In the subsequent study melibiose showed protein-stabilising efficacy
during spray drying and storage. The formulations were physically stable in
the amorphous form. Compared to the current standard excipient trehalose,
protein formulations with melibiose could be spray-dried more efficiently to
drier powders, and protein activity was protected at least equally well. Overall,
melibiose showed promising properties for spray-dried protein formulations.
In the application of Raman spectroscopy for solid state analysis, low-
frequency Raman spectroscopy demonstrated higher sensitivity for solid-state
forms and better quantitative performance compared to conventional mid-
frequency Raman spectroscopy analysis. Pharmaceutical solids, during
processes and storage, can be mixtures of solid-state forms, making reliable
and accurate quantification important. Low-frequency Raman spectroscopy
can be a valuable tool in pharmaceutical solid-state analysis, and provide
improved analytical capabilities even in cases where solid-state forms can be
resolved by mid-frequency Raman spectroscopy.
The other Raman technique, time-gated Raman spectroscopy, was useful
for analysing fluorescent solids and provided a benefit for quantifying their
mixtures. Standard multivariate analysis methods allowed quantitative
analysis, while more recently adopted, kernel-based methods which optimised
the use of the time-gated data, gave superior quantitative results.
In conclusion, melibiose was identified as a promising potential excipient
for stabilising spray-dried protein formulations. Based on this work, melibiose
is worth further investigations with other proteins - and also other materials
requiring stabilisation in the amorphous form - along with longer term storage
stability studies. Further studies regarding the toxicological aspects are also
required before melibiose could be considered for commercial pharmaceutical
products. Low-frequency and time-gated Raman spectroscopies, as well as
kernel-based data analysis, were identified as advantageous methods for
analysing solid-state form composition, also with fluorescent
pharmaceuticals. These techniques can be adopted for various analysis
applications and they could be particularly suitable with spray-dried
biomaterial formulations where solid-state composition is critical for stability
and where fluorescence can be an issue limiting the use of conventional Raman
spectroscopy as a monitoring technique.
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